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1. All the temperatures are expressed in degree centigrade (0C).
2. Melting points of all the compounds are uncorrected and
have been recorded by open capillary method.
3. Room temperature, wherever mentioned, normally corresponds
to 280 - 33 0C.
4. Silica gel-G was used for preparing the TLC plates using
different solvent systems.
5. Infra red spectra  of all the compounds were scanned on
SHIMADZU-FOURIER TRANSFORM INFRA RED(FTIR)-
8400 Spectrophotometer using KBr disc.
6. PMR Spectra were recorded on BRUKER Spectrophotom
eter(400 MHz) using TMS as a internal standard and CDCI3,
and DMSO-d6 as solvents.
7. 13C NMR Spectra were recorded on BRUKER Spectropho
tometer(400 MHz) using  CDCI3,and DMSO-d6 as solvents.
8. MASS spectra were recorded on SHIMADZU-GCMS-QC-
2010.

























1Synopsis...,  “Studies on compounds of medicinal interest”.
 A  comprehensive summary of  the synthetic work is incorporated in the
Ph.D. thesis with the  entitled  “STUDIES ON COMPOUNDS OF MEDICINAL
INTEREST’’ have been  described.  The synthetic work  is presented  in two
parts which is summarized as under.
PART-I ( A) STUDIES ON  4-QUINOLONES.
( B) STUDIES ON PYRIMIDO [2,1-b] [1,3] BENZOTHIAZOLE-
4-ONES.
PART-II STUDIES ON 1,4-DIHYDROPYRIDINES.
PART- I (A) STUDIES ON  4-QUINOLONES.
4-Quinolones exhibit a wide spectrum of pharmacological profile such
as antibacterial, antitubercular, antitumar,  non-nucleoside inhibitors of human
cytomegalo virus, new CB-2 cannabinoid receptors agonists, antimalarials,
antifungal, antiinflammatory. Due to the various biological activities of 4-
quinolones in medicinal chemistry, an attempt has been made to undertake
the synthesis of 4-quinolones in section I to VIII.
SECTION - I: Preparation and biological evaluation of Diethyl-
(substituted phenyl)-aminomethylene malonates.
Diethyl-(substituted phenyl)-aminomethylene malonates (Ia-j) have been
prepared by the cyclocondensation of different substituted phenyl amines and
diethyl ethoxy methylene malonate.










     R=Substituted  phenyl
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Ethyl-substituted-1,4-dihydroquinoline-4-one-3-carboxylates (IIa-j) have
been prepared by the cyclocondensation of different diethyl-(substituted
phenyl)-aminomethylene malonates (Ia-j) in suitable solvent.
SECTION - III: Preparation and biological evaluation of Ethyl-1-N-(2,4-










one-3-carboxylates (IIIa-j)  have been prepared by the cyclocondensation of different
ethyl-substituted-1,4-dihydroquinoline-4-one-3-carboxylates (IIa-j) with 1-chloro-
2,4- dinitro benzene in the basic condition.









     R=Substituted  phenyl
(IIIa-j)
     R=Substituted  phenyl






          Ethyl-6,7,8-substituted-1-N-heptyl-1,4-dihydroquinoline-4-one-3-
carboxylates (IVa-j)  have been prepared by the cyclocondensation of different
ethyl-substituted-1,4-dihydroquinoline-4-one-3-carboxylates (IIa-j) and 1-bromo
heptane in the presence of basic condition.












yl]-substituted quinolone-4(1H)-ones (Va-j) have been synthesized by the
cyclocondensation of  2,3,4,5-tetrafluoro benzoic acid with different substituted-
1,4-dihydroquinoline-4-one-3-carbohydrazides which was prepared by the
action of hydrazine hydrate on ethyl-substituted-1,4-dihydroquinoline-4-one-3-
carboxylates (IIa-j).
SECTION - VI : Preparation and biological evaluation of -3-[4’-
amino-5 ’ - (2 ’’ ,3 ’’ ,4 ’’ ,5 ’’ - te t ra f luorophenyl ) -4H-1 ’ ,2 ’ ,4 ’ - triazol-3’-
yl]- Substituted-quinolone-4(1H)-ones.
(IVa-j)
     R=Substituted  phenyl
  (Va-j)
     R=Substituted  phenyl











Substituted-quinolone-4-(1H)-ones (VIa-j). have been prepared by the
cyclocondensation of different substituted-3-[5’-(2’’,3’’,4’’,5’’-tetrafluoro
phenyl)-1’,3’,4’-oxadiazol-2’-yl]-quinolone-4-(1H)-ones (Va-j) and hydrazine
hydrate.











4-(1H)-ones (VIIa-j) have been prepared by the cyclocondensation of different
substituted 1,4-dihydroquinoline-4-one-3-carbohydrazides with carbon
disulphide and pottassium hydroxide followed by the action of hydrazine
hydrate.




     R=Substituted  phenyl
  (VIIa-j)
     R=Substituted  phenyl














(3’,a-b)[1’,3’,4’]-thiadiazole-3-yl]-quinolone-4(1H)-ones (VIIIa-j) have been
prepared by the cyclocondensation of different substituted-3-[1’-N-amino-2’-
mercapto-1’,3’,4’-triazol-5’-yl)-quinolone-4-(1H)-ones (VIIa-j) and 2,3,4,5-
tetrafluoro benzoic acid in the presence of phosphorous oxychloride.
PART - I (B)
STUDIES ON PYRIMIDO[2,1-b] [1,3] BENZOTHIAZOLE-4-ONES
Pyr imidines and benzothiazoles exhib i t  a wide  spectrum of
pharmacological profile such as antibacterial, antitubercular, antitumar,
antimalarials, antifungal, antiinflammatory. Due to the various biological
activities of Pyrimidines and benzothiazoles, the synthesis of Pyrimido(2,1-
b)[1,3]benzothiazole-4-one having two heterocycles contaning pyrimidine and
benzothiazole moieties have been undertaken which can be symmarized in
the following section.




     R=Substituted  phenyl
  (IXa-j)
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7,8,9-Ethylsubstituted-10a-dihydro-4H-pyrimido[2,1-b][1,3]benzothiazole-
4-one-3-carboxylates (IXa-j) have been prepared by the condensation of different
substituted 2-amino benzothiazoles and diethyl ethoxy methylene malonate.
PART-II STUDIES ON  1,4-DIHYDROPYRIDINES
1,4-Dihydro pyridines are one of the most active class of compounds
possessing diverse biological activi ty viz . ,  calcium chanell  blocker,
cardiovascular, vasodilator, antihypertensive, antitubercular and anti-HIV
activities. Promoted by above facts These valid observations lead us to
synthesize some novel 1,4-dihydropyridines that have been described as
under.




phenyl)-1,4-dihydropyridines (Xa-j) have been prepared by the cyclocondensation
of one mole m-phenoxy benzaldehyde and two moles of substituted-N-phenyl









     R=Substituted  phenyl
7Synopsis...,  “Studies on compounds of medicinal interest”.
SECTION - II: Preparation and biological evaluation of  6-Methyl-2-
isopropyl-4-(substituted phenyl)3-ethyl-5-methyl-1,4-di hydropyridine-
dicarboxylates.
             6-Methyl-2-isopropyl-4-(substituted-phenyl)-5-ethyl-3-methyl-1,4-dihydro
pyridine dicarboxylates (XIa-j) have been prepared by the cyclocondensation
of one mole of ethyl-3-amino but-2-enoate and one mole of methyl-2-
substituted-benzylidene-4-methyl-3-oxo-pentanoates.
















substituted phenyl-1,4-dihydropyridine-5-carboxylates (XIIa-j) have been














     R=Substituted  phenyl
                      (XIIa-j)
    R & R1= Substituted phenyl
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and different one mole of 2-substituted-benzylidene-4-methyl-3-oxo-N- phenyl
pentanamides.
PURIFICATION AND CHARACTERISATION:
The purity of all the newly sythesized compounds have been checked
by thin layer chromatography and constitution of newly synthesised compounds
(Ia-j ) to (XIIa-j) have been delineated by Elemental analysis, FT IR, 1H
NMR,13C NMR and Mass spectroscopy.
ANTIMICROBIAL  ASSAY:
All the newly sythesized compounds (Ia-j) to (XIIa-j) have been screened
for their in vitro therapeutic assay like antibacterial activities towards gram
positive and gram negative bacterial strains and antifungal activites at different
concentrations (minimum inhibitory concentration). The biological activites
of synthesizied compounds have been compared with standard drugs.
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“STUDIES ON COMPOUNDS OF MEDICINAL
INTEREST’’
(A) Drug
The word drug is derived from the French word “drogue” which means
‘a dry herb. It is the single active chemical entity present in a medicine that
is used for diagnosis, prevention, treatment / cure of a disease. This dis-
ease oriented definition of drug does not include contraceptives or use of
drugs for improvement of health. According to “WHO” a drug may be defined
as “Any  substance or product which is used or intended to be used for modi-
fying or exploring physiological system as pathological status for the benefit
of the recipient”.
(B) Pharmacology
Pharmacology is the science of drugs. In a broad sense, it deals with
interaction of exogenously administered chemical molecules (drugs) with
living system. It encompasses all aspects of knowledge about drugs, but most
importantly those that are relevant to effective and safe use for medicinal
purposes. For thousands of years most drugs were crude natural products of
unknown composition and limited efficiency. Only the over effects of these
substances on the body were rather imprecisely known, but how the same were
produced was entirely unknown. Over the past 100 years or so, drugs have
been purified, chemically characterized and a vast variety of highly potent and
selective new drugs has been developed. The two main divisions of
pharmacology are pharmacodynamics and pharmacokinetics.
(a) Pharmacodynamics : It is derived from the Greek word “dynamic”
means power. What the drugs does to the body? This includes physiologi-
cal and biochemical  ef fects of  drugs and their  mechanism of  act ion
at macromolecular / sub cellular organ systems.
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(b) Pharmacokinetics : It is derived from the Greek word ‘Kinesis’
means movement. What the body does to the drug? This refers to move-
ments of the drug in and alternation of the drug by the body; includes ab-
sorption, d ist r ibut ion,  b inding /  local izat ion /  s torage,  b iotransforma-
t ion and excretion of the drug.
Some other important aspects of pharmacology are given as under.
* Pharmacotherapeut ics  :  I t  i s  t he  app l i ca t i on  o f  pha rmaco-
dynamic  i n fo rma t i on  t oge the r  w i t h  know ledge  o f  t he  d i sease  fo r
i t s  p reven t ion ,  m i t i ga t i on  o r  cu re .
* Clinical Pharmacology : It is the scientific study of drug in man.It
includes pharmacodynamic and pharmacokinetic investigation in healthy
volunteers and in patients; evaluation of efficiency and safety of drugs and
comparative trials with other forms of treatments; surveillance of patterns of
drug uses, adverse effects, etc.
* Chemotherapy : It is the treatment of systemic infection / malignancy
with specific drugs that have selective toxicity for the infecting  organism /
malignant cell with less effect on the host cells.
?  Drugs in general, can thus be divided into :
* Pharmacodynamic agents :  These are chemical substances
designed to have pharmacodynamic effect in the recipient.
* Chemotherapeutic agents : These are chemical substances designed
for the treatment of infectious diseases or by the proliferation of malignant cells.
(c) Essential Drug Concept: The ‘WHO’ has defined Essential Drugs
as “those that satisfy the healthcare needs of majority of the population; they
should therefore be available at all times in adequate amounts and in
appropriate dosage form”.
I t  has been real ized that only a handful  of  drugs out of  the
multitude available can meet the health needs of majority of the people in any
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country, and that may be well tested and cheaper drugs are equally (or more)
efficient and safe as their newer more expensive congeners. For optimum
utilization of resources, governments (specially in developing countries) should
concentrate on these drugs by identifying them as Essential Drugs. The “WHO”
has laid down criteria guide selection of an essential drug :
(I) Adequate data on its efficiency and safety should be available from
          clinical studies.
(II) It should be available in a form in which quality, including bioavailability and
stability on storage can be assured.
(III) Its choice should depend upon pattern of prevalent diseases; avail
ability  o f  fac i l i t ies  and t ra ined personne l ;  f inanc ia l  resources;
genet ic ,  demographic and environmental factors.
(IV) In case of two or more similar drugs, choice should be made on the
basis of their relative efficiency, safety, quality, price, availabil ity
and cost benefit ratio should be a major consideration.
(V) Choice may also be influenced by comparative pharmacokinetic proper
ties and local facilities for manufacture and storage.
(VI) Most essential drug should be single compound. Fixed ratio combina
tion products should be included only when dosage of each ingredient
meets the requirements of a defined population group, and when the
combination has a proven advantage.
(VII) Selection of essential drug should be a continuous process which should
take into account the changing priorities for public health action, epide-
miological condition as well as availability of better drugs/ formulations
and progress in pharmacological knowledge.
(C)  Drug Development
Many natural products by trial and error, came into practise for combat-
ing human ailments existent during early human observation. With the advent
of modern scientific approach, various plant medicines came under chemical
scrutiny, ultimately leading to the isolation of active principles since early.
Such compounds either in extract form or in pure form became a part of
pharmacopoeias. For instance, though the Chinese drug, Mauhang was in use
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for over 5000 years for the treatment of various types of fever and respiratory
ailments, its active principle, Ephidrine was isolated in 1887. In 1925 chemi-
cal investigations followed by pharmacological evaluation led this compound
into the modern medicine. Similarly during this period, urea stibamine was
introduced as the first drug in 1920 for the treatment of Kala-azar. In 1930, De
Rauwolfia preparation were first employed for sedative and hypotensive prop-
erties.
A drug is a substance having abnormal effect on certain body functions
eg. Strychnine stimulates the action of heart and aspirin retards its action.
Since both of them effects abnormally, the two substances are known as drugs.
Chemical sciences contributed extensively new discoveries leading to useful
drugs since after 1930. The modern concept of drug discovery started in 1933
by Gerhand Domagk with his finding of “Prontosil Red”, a compound respon-
sible for the antibacterial activity. The advent of sulphonamides drew the at-
tention for the different activities of various chemicals for bacterial and human
cells, this important factor prompted Florey and Chain in 1939 to investigate
penicillin which was discovered ten years earlier by Alexander Fleming. The
spectacular chemotherapeutical properties of penicillin and its dramatic
war-time development for the treatment of wounds made penicillin, a most
commonly used inexpensive drug.
           A large number of important drugs have been introduced during the
period of 1940 to 1980. This period is known as “Golden period” of new drug
discovery. Thus starting from 1933 - the first antibacterial drug prontosil lead-
ing to various  sulpha drugs; 1940 – penicillin; 1945 – chloroquine – anti-
malarial; 1950 – Methyldopa – anti-hypertensive; 1967 – chlorothiazine
-diuretic; 1958 - adrenergic beta blockers coronary vasodilatory; 1960 - semi
synthetic penicillin -antibacterial; 1965 -trimethoprim-antimicrobial;1967-
disodium chromoglycoate - antiallergic; 1972 - cimetidine H2– antagonist;
1975 -verapamil- calciumantagonist and 1981 - captopril - antihypertensive.
There are some specific examples representing new  therapeutic agent  eg. Metormine
glipizide-antidiabetic.
(D) Latest Drug Developments
The current interest in the creation of large, searchable libraries of
organic compounds has captured the imagination of organic chemists and
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the drug discovery community. In numerous laboratories the efforts are focused
on the introduction of chemical diversity, which have been recently reviewed
and pharmacologically interesting compounds have been identified from li-
braries of widely different compositions.
Today, the chief source of agents for the cure, the mitigation or the
prevention of diseases are the organic compounds, natural or synthetic, to-
gether with so-called organometallics. Such agents have their origin in a num-
ber of ways (a) from naturally occurring materials - of both plant and animal
origin, and (b) from the isolation of organic compounds synthesized in labora-
tory whose structures are closely related to those of naturally occurring com-
pounds for eg. atropine, steroids, morphine, cocaine etc. that have been
known to possess useful medicinal properties.
The process of drug design is extensively driven by the instinct and ex-
perience of pharmaceutical research scientists. It is often instructive to at-
tempt to “capture” these experiences by analyzing the historical record that
are successful drug design projects of the past. From this analysis, the infer-
ences are drawn which play an important role in shaping our current and future
projects. Towards this region, we would like to analyse the structures of a large
number of drugs - the ultimate product of a successful drug design effort. Our
goal for this is to begin to deconvolute this information in order to apply it to
design of new drugs.
Different kinds of drugs are developed for different types of diseases
viz. which can be defined with their names of the modern drugs are as under.
(a) Anticancer drugs
The drugs, which stops the abnormal growth of cell tissues in human
body, are termed as anticancer drug. Vinblastin and Busulphan are the novel
anticancer drugs.
(b) Hepatoprotective drugs
Drugs, which gives vitality to liver and protects liver by giving immunity
power against antibodies, are termed as Hepatoprotective drug.
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(c) Antimalarial drugs
Drugs, which kills the plasmodium causing malaria are called antima-
larial drug. Combination of Sulphamethoxazole with Pyrimethamine is a
novel antimalarial drug.
(d)      Drug for meningitis
Drugs, which cures the inflammation of meningitis, are termed as
meningitis drugs Cifalexin is a novel meningitis drug.
(e)      Drug for typhoid
Drugs, which kills the bacteria of Salmonella typhi causing typhoid are
known as typhoid drugs. A novel drug for typhoid is Ciprofloxacin.
(f)       Antidiabetic drugs
Drugs, which converts the excess glucose of blood into glycogen are
termed as antidiabetic drugs. Novel antidiabetic drugs are Metformin,
Glipizide and Gliclazide.
(g) Antitubercular drugs
Drugs, which kills the bacteria of mycobacterium tuberculosis and thus
cures lesions of pleural cavity. A novel antitubercular drug is Ethambutol.
(h) Antiasthamatic drugs
             Drugs, which prevents the attack of asthama and gives relax respira-
tion are called antiasthamatic drugs. Novel antiasthamatic drugs are
Ethophylline, Theophylline and Asmon.
(i) Antihypertensive drugs
            Drugs, which normalizes the blood pressure by dilating blood vessels
are cal led ant ihypertensive drugs. Novel ant ihypertensive drugs are
Atenolol,  Amlodipine and Nifedipine.
(j)        Anti-AIDS drugs
          Drugs, which kills the viruses of AIDS i.e., HIV-1 and HIV-2 are called
anti-AIDS drugs. Novel drugs are Zidovudine, Acyclovir and Didanosine.
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           Drugs, which neutralize the acid in stomach and stops excessive
secretion of acid, are called antacid drugs. Novel antacid drugs are
Omeprazole and Lansoprazole.
(l)      Non steroidal antiinflammatory drugs (NSAID)
Drugs, which gives relief from fever, pain and inflammation are called
NSAID. Novel NSAID are Pyroxicam, Meloxicam and Nimesulide.
Different kind of drugs generally used are designed as anaesthetic,
ant i tuberculostat ic,  ant ihypertensive, ant iconvulsant,  anthelmint ic,
antiinflammatory, sedative and hypnotics which prompted us to synthesise
drugs having 4-quinolones, pyrimido[2.1-b][1,3]benzothiazole-4-ones and
1,4-dihydro pyridines moieties as a better therapeutic activity.
? Aims and objectives of the present investigation are as follows.
(a) To generate several biologically active moieties such as 4-quinolones,
pyrimido[2.1-b][1,3]benzothiazole-4-ones and 1,4-dihydro pyridines.
(b) To characterize these products for their structural assignment using
various spectroscopic techniques like IR, PMR and Mass spectroscopy.
(c) To screen these new derivatives for their antimicrobial activity using
different s t ra ins  o f  bacter ia  and fung i  and to  compare ant imicrob ia l
ac t iv i ty  with different known drugs at different concentrations for their MIC
values.
In view of these facts, the research work presented in thesis are as
follows.
PART-I ( A) STUDIES ON  4-QUINOLONES.
( B) STUDIES ON PYRIMIDO [2,1-b] [1,3] BENZOTHIAZOLE
                            -4-ONES.











Benzene ring when fused with 2,3-position of pyridine nucleus is known
as quinoline. Quinoline carboxylic acid in which quinoline ring is substituted
by oxo and carboxylic acid group at different positions are well documented in





Quinolones constitute a large class of synthetic antimicrobial agents
that are highly effective in the treatment of many types of infectious diseases,
particularly those caused by bacteria. Quinolones are potent, broad specturem
antibacterial agents. The early congeners of the quinolone antibiotics which is
non-fluorinated at C-6 like nalidixic acid were limited to certain gram negative
infections such as urinary tract infections. However, the modern generation of
fluoroquinolones containing C-6 fluoro substituent and a cyclic basic amine
moiety at C-7 surpass their predecessors in terms of spectrum of activity and
potency. This has allowed for their use against a variety of gram-negative as
well as some gram-positive pathogens. Quinolones are relatively easily pre-
pared and administered via parenteral and oral routes and are well tolerated.
The rapid rise in bacterial resistance to the traditional antibiotics such
as penicillin and tetracyclines and their derivatives has encouraged a continu-
ing search for new classes of compound with novel modes of antibacterial
activity.
The 4-quinolone antibiotics have emerged as an area of immense in-
terest because of their broad spectrum of the in vivo activity and their in-
vivo chemotherapeutic efficiency. Various structural modifications of this class
of compounds have provided the new agents such as ciprofloxacin1,
ofloxacin2, lomefloxacin3 and sparfloxacin4 which are considerably more po-
tent and have a broader spectrum of antibacterial activity.












Indicate milestiones in antibiotic
drug development.
Discovery of penicilin by alexa
nder fleming.
Discovery of the sulpha drugs.
Penicilline the first b-lactam drugs,
launches the antibiotic era.
Streptomycine, an aminoglyco




aminogycosides neomycin and gen-
tamicin are introduced.
Macrolides such as erythromycin
enter the market.
The first glycopeptide vancomycin
is approved.
The rifamycin family of anti biotics
is discovered.
The dihydrofolate reductase inhi
bitor drug trimethoprim is launched.
Indicate landmarks in the evolu-
tion of bacterial  resistance.
         Staphylococcus aureus
shows resistance against penicilin.
          Isolates of erythromycin resi
stant staphylococci reported in jap-
an, england, france and the USA.
         Methicillin-resistant S. aureus
(MRSA) detected in the UK.
RACE-AGAINST TIME : THE INTRODUCTION OF NEW ANTIBIOTIC CLASSES
AND THE EMERGENCE OF RESISTANCE.5













The quinolone and the streptogra
mins are discovered.
Cefalexin, a first-generation cepha-
losporin, is launched.
The first fluoroquinolone, norfloxac
in, is approved for human use.
Linezolid, first in the novel oxazoli
dinone class of antibiotics, is approved.
A new lipopeptide antibiotic, dapt
omycin, is approved.
          Penicillin-resistant Neisseria
gonorrhoeae and Streptococcus
pneumoniae reported.
        MRSA develops resistance to
cephalosporins.
         Penicillin-resistant  Entero-
coccus faecium is detected.
        Vancomycin-resistant entero-
cocci is detected.
        (Early 1990s) Multi-drug-resis-
tant Pseudomonas aeruginosa
seen in hospital-acquired infections.
        First vancomycin-resistant strain
of S. aureus is detected in japan.
           Isolation of linezolid-resistant
enterococci.
      (Early 2000s) Community -ac-
quired MRSA recognized as an
emerging pathogen.
        Linezolid-resistant  S. aureus
is reported.
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SYNTHETIC  METHODS OF 4-QUINOLONES:-
Oldfield William (1969) synthesized 1-phenyl-4-oxo-1,4-dihydro-
quinoline-3-carboxylic acids6. Different synthetic methods for the synthesis of
4-quinolone reported in the literature are as under:
(A). By the ethylation of 4-quinoline-3-carboxylic acid7.
(B). By the treatment of substituted acetophenones with ethylcarbonate and
triethylorthoformate followed by the condensation with substituted phenyl
amine and further cyclization to afford 4-quinolone derivatives8.
(C). By the reduction of 4-(3-nitro phenyl)pyridine followed by the conden-
sation with diethyl ethoxy methylene malonate and on further cyclization
yields substituted 4-quinolone-3-carboxylic acids9.
(D). By the condensation of substituted anilines with dimethyl acetylene di
carboxylate followed by thermal cyclization and hydrogenation10.
(E). By the heating 4-Fluoro-2-methyl-N-(2,2,2-trif luoroethyl) anil ine
with po lyphosphor ic  ac id  a t  110º  C to  g ive 6- f luoro-4-oxo-1-
(2,2,2-trifluoroethyl)-1,4-dihydroquinoline-3-carboxylic acid11.
(F). By the condensation of 2,5-C2H5-(NH2)C6H3O(CH2)17CH3 with diethyl
ethoxy methylene malonates followed by the cyclization with phosporous
oxychloride to afford substituted quinolone-3-carboxylic acids12.
(G). By the reaction of diethylethoxy methylene malonates with secondary
` aromatic amine in the presence of polyphosphoric acid to gives 4-
quinolone-3-carboxylic acid13.
(H). By the heating of N-(b-dicarboxy ethyl ethylene)-substituted aniline on
heating at  250-255º C affords 4-quinolone-3-carboxylic acid 14.
(I). By the condensation 2,4-dichloro-5-fluoro benzoyl chloride  with malonic
ester followed by decarboxylation and condensation with ethyl formate
which on treatment with cyclopropyl amine followed by cyclization and
reaction with piperazine yields ciprofloxacine15.
(J). By the reaction of substituted acid chloride with diethyl malonate in the
presence of magnesium followed by cyclization16.
(k). By the reaction of N-Hydroxy succinimide ester of anthranillic acid with
anions of ß-keto esters to give 4-oxo-3-quinoline carboxylic acid derivatives17.
(L). By the reaction of ß-keto ester with p-anisidine in polyphosphoric acid
affords 2-(phenoxy difluoromethyl)-6-methoxy 1H-quinoline-4-one18.
(M). 3-amino-2-phenyl-4(1H)-quinolones are obtained from anthranilamides19.
(N). By the condensation of substituted acetophenones with cyclopropyl
amine and dimethyl sulphate followed by the cyclization to afford 4-
quinolone-3-carboxylates20.








































(1) Nadifloxacin (antibacterial) (2) Ciprofloxacin
(3) Gatifloxacin (antibacterial) (4) Satifloxacin
(5) Ofloxacin(antibacterial) (6) Garenoxacin
(7) Gemifloxacin (8) Nalidixic acid (Urinary tract infe.)
(9) Cinoxacin (10) Norfloxacin (Gyrase inhibitor)
(11) Enoxacin (Gyrase inhibitor) (12) Lomefloxacin
(13) Temafloxacin (14) Pefloxacin (Gyrase inhibitor)
(15) Enrofloxacin (16) Flumequine
(17) Tosufloxacin (18) Pipemidic acid (Urinary tract infe.)
(19) Amifloxacin (20) Oxalinic acid (Gyrase inhibitor)
(21) Miloxacin (22) Difloxacin
(23) Fleroxacin (24) Alatrofloxacin mesilate
(25) Grepafloxacin (26) Rufloxacin(antibacterial)
(27) Rosoxacin (antibiotic) (28) Piromidic acid (chemotherapeutic)
(29) Flose quinon (vasodilator) (30) Nedocronil (Antiallergic)
Some of the important 4-quinolones which are used in chemical trial can
be summarized as under with several structures21.
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STRUCTURE- ACTIVITY RELATIONSHIP
The quinolone carboxylic acids constitute a class of extremely potent
and orally active broad spectrum antibacterial agents22-25. These compounds
have been shown to affect the bacterial growth by inhibiting the DNA gyrase, a
key enzyme in bacterial DNA replication26-27.
The substituiton of a piperazinyl ring at position 7 has rendered the mol-
ecule active against Pseudomonas and the presence of a fluorine atom at
position 6 extends the activity of the molecule to some but not all gram-posi-
tive bacteria29. Streptococcus can be resistant28. Additions of alkyl chains to
the nitrogen at position 1, increase the activity of the compounds. The substi-
tution of hydrogen atoms by fluorines at position 8 of the ring and on the me-
thyl of the alkyl chain diminishes the rate of degradation and decreases the
rate of elimination.
It was widely believed  that 3-carboxylic acid and 4-carbonyl were nec-
essary for the antimicrobial activity of the compounds. However, Chu et.al.,30
a showed that the transformation of exist ing molecules in 2,3,4,9-
tetrahydroisothiazolo[5,4-b] quinoline-3,4-diones produces a significant in-
crease in their biological activity31.










Moderate Influence on 
potency Cardiotoxicity Essential For gyrase binding




Controls Pk (oral abs).:
Phototoxicity
Infuences potency and 
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1. Subtituent at N-1 position: A compilation of active N-1 quinolone substituents
is shown below with an emphasis on overall in vitro potency.
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2. The simple replacement of C-2 hydrogen has general ly to be
disadvantageous,e.g., C-2 methyl or hydroxyl groups. However, some deriva-
tives containing a suitable C-1 and C-2 ring have been shown to possess no-













3. Without doubt, the C-3 carboxylic acid moiety is most commonly en-
countered. Other acidic groups such as sulphonic acid, phosponic acid,
tetrazole as well as derivatisation as an ester results in a loss of antibacterial
activity.
4. The C-4-oxo group of the quinolone nucleous appears to be essential
for antibacterial activity. Replacement with 4-thioxo or sulphonyl group leads
to a loss of activity.
5. The incorporation of an amino group at the C-5 position has proven to
be benefical in terms of antibacterial activity. The order of activity at R3: NH2,
CH3>F, H>OH, OR, SH, SR.
6. The incorporation of a fluorine atom at the C-6 position of the quinolone
is monumental, the order of activity at  R4: F.>Cl,  Br, CH3 >CN.
7. The introduction of a piperazine moiety at C-7 was a landmark
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8. A hydrogen atom at the C-8 or a nitrogen atom (a napthyridone) is the
most common. In general, a C-8 fluoro substitutent offers good potency against
gram-negative pathogens, while a C-8 methoxy moiety is active against gram-
positive bacteria. The order of activity at R6; F, Cl, OCH3, >H, CF3> methyl,
vinyl, propagyl.
9. A halogen (F or Cl) at the 8-position improves oral absorption.
10. The joining of N-1 group to the C-8 position with oxazine ring leads to
active ofloxacine.
MEDICINAL INTEREST OF 4-QUINOLONES
The research on 4-quinolones system is of current interest due to their
valuable activities as Antibiotic, DNA gyrase inhibitors, Antibacterial  etc. Be-
sides the currently established drugs like Norfloxacin ,Ciprofloxacin. Many 4-
quinolone derivatives have been synthesized world wide and have led to nu-
merous second generation commercial product such as Ofloxacin, Gatifloxacin,
Pipemidic acid. By the literature survey, it was found that 4-quinolones possess
wide variety of biodynamic activity, which can be put forward as under.
[A]  Analgesic activity34-37
[B]  Antiallergic activity38-42
[C]  Antiasthmatic activity43-44
[D]  Antibacterial activity45-63
[E]  Anticancer activity64
[F]  Anticoccidial activity36,49,65-66
[G]  Antiinflammatory activity67-68
[H]  Antinaphylatetic activity69
[I]    Antipyretic activity34
[J]   Antirheumatism activity34
[K]   Antispasmolytic activity70
[L]   Antitumor activity71-73
[M]  Antiulcer activity74
[N]  Bacteriostatic activity76
[O]  CNS depressant activity35,77
[P]  Diuretic activity77-78
[Q]  Hypnotic activity79
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[R]  Hypotensive activity35
[S]  Pressure lowering activity80
[T]  Tranquilizer activity78
[U]  Tuberculosis activity80-81
[V]   Antimalarials82
[W]  Topoisomerase inhibitors83-84
[X]  CB2 cannabinoid receptors agonists85
Recently, K.S.Aithal et.al.,86 have reported uses of norfloxacin for bone
joint urinary tract, respiratory tract infection and also for maningitis. Antimi-
crobial and antifungal activity of 4-quinolones have been reported by
M.B.Deshmukh et.al.,87-88  Antiallergic activity studies of quinolone (6) and
imidazoquinolinones (7) have been reported by N. P. Peet et.al.,41  which established
the SAR conclusion that amine and ester functions at the position 8 and 3 respectively
















H. Takayama et.al.,89 have isolated new alkaloid (8) from leaves of Gardneria











The alkaloid was obtained from crude basic fraction of the leaves of
gardne -ria nutans in its unique structure having a 4-quinolone moiety.
R. Singh et. al.,90  have reported the synthesis and antibacterial activity
of 7-hydrazinoquinolones (9).












G. Gruver et. al.,32  have designed  the synthesis of  1,3,4-oxadiazoles
and 1,3,4-oxadiazole-2-thione derivatives of nalidixic acid (10) and (11) as
potent antibacterial and fungicidal agents.
     
(10) (11)


















C. Zhi  et. al.,84 have reported the synthesis of  a novel hybrid antibac-
ter ia l  agent (12)  of  6-(3-ethyl-4-methylani l ino)uraci ls  (EMAU) and
fluoroquinolones moiety (FQ) as potent DNA  polymerase- topoisomerase in-
hibitors and showed that the resulting AU-FQ hybrid compounds were signifi-




















Recently, synthesis antimicrobial activity studies of novel amide deriva-
tives of 4-quinolone (13) and (14) have been reported by H. I. Chauhan et.al.,20.
R and R1=substituted phenyl, X=N,


















A. Carta et.al.,91 have studied the antitubercular activity of some new
(1,2,3)- triazolo (4,5-h) quinolones (15) aganist the multidrug resistant Myco-









Recently, antimycobacterial and toxicological evaluation of novel










In our further studies and in order to evaluate the biodynamic activities, synthe-
sis of 4-quinolone derivatives was undertaken,  which can be summarised in the fol-
lowing sections.
R and R1=substituted phenyl
R and R1=substituted phenyl
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SECTION - I: PREPARATION AND BIOLOGICAL EVALUATION OF
DIETHYL-(SUBSTITUTEDPHENYL)-AMINO METHYLENE-
MALONATES.
SECTION - II: PREPARATION AND BIOLOGICAL EVALUATION OF
ETHYL-SUBSTITUTED-1,4-DIHYDROQUINOLINE-4-
ONE-3-CARBOXYLATES.
SECTION - III: PREPARATION AND BIOLOGICAL EVALUATION OF ET
HYL-1-N-(2,4-DINITRO-PHENYL)-6,7,8-SUBSTITUTED-
1,4-DIHYDROQUINOLINE-4-ONE-3-CARBOXYLATES.
SECTION - IV : PREPARATION AND BIOLOGICAL EVALUATION OF
ETHYL-6,7,8-SUBSTITUTED-1-N-HEPTYL-1,4-DIHY-
DRO QUINOLINE-4-ONE-3-CARBOXYLATES.




SECTION - VI : PREPARATION AND BIOLOGICAL EVALUATION OF
-3- [4 ’ -AMINO-5’ - (2 ’’ ,3 ’’ ,4 ’’ ,5 ’ ’ -TETRA FLUORO
PHENYL)-4H-1’,2’,4’-TRIAZOL-3’-YL]- SUBSTIT-
UTED-QUINOLONE-4(1H)-ONES.
SECTION - VII : PREPARATION AND BIOLOGICAL EVALUATION OF
3-[1’-N-AMINO-2’- MERCAPTO-1’,3’,4’-TRIAZOL-5’-YL)-
SUBSTITUTED-QUINOLONE-4-(1H)-ONES.
SECTION - VIII : PREPARATION AND BIOLOGICAL EVALUATION OF
SUBSTITUTED-3-[6’-(2’’,3’’,4’’,5’’,-TETRAFLUORO
PHENYL)(1’ ,2, ’ ,4’ ) -TRIAZOLO-(3’ ,a-b) [1’ ,3’ ,4’] -
THIADIAZOLE-3-YL]-QUINOLONE-4(1H)-ONES.
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SECTION - I
PREPARATION  AND  BIOLOGICAL EVALUATION OF DIETHYL-(SUBSTI-
TUTED PHENYL)-AMINOMETHYLENE MALONATES.
Keeping in view of various biodynamic activities34-85 of 4-quinolones
and in order to have highly potent therapeutic agents, the synthesis of Diethyl-
(substituted phenyl)-aminomethylene malonates (Ia-j) have been under-
taken by  the condensation of different substituted phenyl amines and di-
ethyl ethoxy methylene malonate.
The constitution of the products (Ia-j)  have been delineated by elemental
analyses, IR, PMR and Mass spectral data.
The products (Ia-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 , S. aureus MTCC-96
and B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443  (Gram
negative) bacterial strains and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations.i.e.:
0(control), 5, 25, 50, 100, 250 (μg/ml)  for their MIC (Minimum Inhibitory Con-
centration) values. The biological activities of the synthesized compounds
(Ia-j) were compared with standard drugs viz., Amoxicillin, Chlorampheni-
col, Sparfloxacin, Levofloxacin(antibacterial), Griseofluvin, Fluconazole
(antifungal).
 ( Ia-j )
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EXPERIMENTAL
PREPARATION AND  BIOLOGICAL EVALUATION OF DIETHYL-(SUBSTI-
TUTED PHENYL)-AMINOMETHYLENE MALONATES.
(A)     Preparation of  Diethyl-(3-chloro-4-fluoro phenyl)-amino meth-
ylene malonate (ld).
A mixture of 3-chloro-4-fluoro aniline (2.60 gm, 0.01 M) and diethyl ethoxy
methylene malonate (1.06 ml, 0.01M) in ethanol (20 ml) was heated under reflux
condition for 5 hrs. The rection mass was cooled at 0 to 5 OC  temperature.The
reaction mixture was poured into ice-water, filtered and washed with water
and crystallized from ethanol. Yield : 84 %, M.P. : 64 OC,  (Required : C, 53.26%;
H, 4.79% N, 4.44%; for C14H15NO4ClF, Found : C, 53.20%; H, 4.74% N, 4.40%.
TLC  solvent system  Rf1  : Ethyl acetate : Hexane (2.0 : 8.0)  = 0.62.
TLC  solvent system  Rf2  :  Methanol       : Toluene (0.5 : 9.5)  = 0.46.
Similarly, other compounds (Ia-j) were synthesized. The physical data
are recorded in Table No. 1.
(C) Antimicrobial activity of Diethyl-(substitutedphenyl)-amino meth-
ylene malonates (Ia-j).
Antimicrobial activity testing was carried out by using cup-plate
method93, which has been described as under.
Antibacterial activity
S. pyogens MTCC-442 ,S. aureus MTCC-96 and B. subtillis MTCC-
441 (Gram positive bacteria) were grown in nutrient broth and E. coli MTCC-
443 (Gram negative bacteria) in Peptone water (PW, 1% bacteriological pep-
tone and 0.5% NaCl in water) for 24 hrs., this gave an optimum growth of the
test  bacteria. Each purified compound was dissolved in dimethyl formamide
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sterilized by filtration by using sintered glass filter and stored at 4OC. Each
agent was then added to molten nutrient agar in the following concentrations i.e,
: 0 (control), 5, 25, 50, 100, 250 (μg/ml) and poured into sterile petridishes. The
pH of the media was maintained at 7.2 -7.4. The inoculum consisted of an
overnight grown broth culture of a bacterium diluted in such a manner that a 2
m.m. (internal diameter) loopful of the culture contain 105 colony-forming unit
(CFU). These were then spot inoculated on nutrient  agar  plates containing
increasing amount of a  compound, incubated at 37OC for 24 hrs. For deter-
mination of the minimum inhibitory concentration94-95(MIC). Which are re-
corded as zones of inhibition in m.m. for bacterias in Table No. 1A, 1B.
Antifungal activity
C. albicans MTCC-227 and A. niger MTCC-282 was employed for
testing antifungal activity using cup-plate method. The culture was maintained
on Sabouraud's agar for 72 hrs., this gave an optimum growth of the test fun-
gal spores. Each purified compound was dissolved in dimethyl formamide ster-
ilized by filtration by using sintered glass filter and stored. Each agent was
then added to Sabouraud's agar in the following concentrations i.e,: 0 (con-
trol), 5,  25, 50, 100, 250 (μg/ml) and poured into sterile petri dished. The
inoculum consisted of an overnight grown broth culture of a bacterium diluted
in such a mannerso that a 2 m.m. (internal diameter) loopful of the culture con-
tain 105 colony-forming unit (CFU). These were then spot inoculated on
Sabouraud's agar plates containing increasing amount of a compound, incu-
bated at 37OC for 48 hrs. For determination of the minimum inhibitory concen-
tration (MIC)94-95. Which are recorded as  zones of inhibition in m.m. for fungi
in Table No. 1C.














































































































































   



































   



































   





































   





































   





































   





































   

































   




   





































   

































   













































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
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IR SPECTRAL STUDY OF DIETHYL-(3-CHLORO-4-FLUOROPHENYL)-









































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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C-H (asym. str., m s)
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* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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NMR SPECTRAL STUDY  OF DIETHYL-(3-CHLORO-4-FLUOROPHENYL)-
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NMR SPECTRAL STUDY OF DIETHYL-(3,4-DICHLOROPHENYL)-
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SECTION - II
PREPARATION AND  BIOLOGICAL EVALUATION OF ETHYL-(SUBSTI-
TUTED-1,4-DIHYDROQUINOLIN-4-ONE-3-CARBOXYLATES.
Keeping  in  view of various b iodynamic  ac t i v i t i es34-85 o f  4-
quinolones and in order to have highly potent therapeutic agents, the synthe-
sis of Ethyl-substituted-1,4-dihydroquinolin-4-one-3-carboxylates (IIa-j)
have been undertaken by the condensation of different diethyl-(substituted
phenyl)-aminomethylene malonates (Ia-j)  in dimethyl sulphoxide.






The constitution of the products (IIa-j)  have been delineated by elemental
analyses, IR, PMR and Mass spectral data.
The products (IIa-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442, S. aureus MTCC-96
and B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations .i.e.:
0(control),  5, 25, 50, 100, 250 (μg/ml)  for their MIC (Minimum Inhibitory
Concentration) values. The biological activities of the synthesized compounds




      R=Substituted  phenyl
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF  ETHYL-(SUBSTI-
TUTED-1,4-DIHYDROQUINOLINE-4-ONE-3-CARBOXYLATES.
(A)     Preparation of  Diethyl-(3-chloro-4-fluoro amino phenyl)-amino-
methylene malonate (ld).
Refere preparation, in Part-1, Section-I, page No. 30.
(B) Preparation of Ethyl-(7-chloro-6-fluoro-1,4-dihydroquinoline)-4-
one-3-carboxylate (lId).
A mixture of Diethyl-(3-chloro,4-f luorophenyl)-aminomethylene
malonates (ld) (3.15 gm,0.01M) and dimethyl sulphoxide (20 ml) was heated
under stirring at 190 to 210OC. The resulting mixture was then refluxed for 8
hrs. The reaction mixture was allowed to cool at room temperature. The reac-
tion mixture was poured into ice-water, filtered and washed with water and
crystalized from dimethyl formamide. The product was dried at 50-55 OC the
white crystalline powder.. Yield : 53 %, M.P. : 289 OC, (Required: C, 53.45 %;
H, 3.36 %; N, 5.19 %  for C12H9NO3ClF, Found: C, 53.41 %; H, 3.31 %; N,
5.17 %).
TLC  solvent system  Rf1  : Ethyl acetate : Hexane (3.0 : 7.0) = 0.60.
TLC  solvent system  Rf2  : Methanol        : Toluene (2.0 : 8.0) = 0.46.
Similarly, other compounds (IIa-j) were synthesized. The physical data
are recorded in Table No. 2.
(B) Antimicrobial activity of Ethyl-(substituted-1,4-dihydroquinoline)
-4-one-3-carboxylates (IIa-j).
Antimicrobial activity testing was carried out as described in Part-1(A),
Section-I, page No. 30-31. The MIC values of test solution are recorded in
Table No. 2A, 2B and 2C.
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* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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IR SPECTRAL STUDY OF ETHYL-6-NITRO-1,4-DIHYDRO QUINO-















































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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NMR SPECTRAL STUDY OF  ETHYL-6 -FLUORO-1 ,4 -D IHYDRO-
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NMR SPECTRAL STUDY OF  ETHYL-7 -CHLORO-1 ,4 -D IHYDRO-
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 C6H6  C9H8O3
(B.P),
(IIb),











































































































































































































































































































































































































































 C4H7NO2  C12H10N2O5
 C5H7NO2
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SECTION - III
PREPARATION AND BIOLOGICAL EVALUATION OF ETHYL-1-N-(2,4-
DINITRO-PHENYL)-6,7,8-SUBSTITUTED-1,4-DIHYDROQUINOLINE-4-
ONE-3-CARBOXYLATES.
Keeping in view, various properties34-85 of 4-quinolone and in order
to have highly potent therapeutic agents, the synthesis of Ethyl-1-N-(2,4-
dinitro phenyl)-6,7,8-substituted-1,4-dihydroquinoline-4-one-3-carboxy-
lates (IIIa-j)  have been accomplished by the cyclocondensation of different ethyl-
substituted-1,4-dihydroquinoline-4-one-3-carboxylates (IIa-j) with 1-
chloro-2,4-dinitro benzene in the basic condition.








The constitution of the products (IIIa-j) have been delineated by elemen-
tal analyses, IR, PMR and Mass spectral data.
The products (IIIa-j)  were assayed for their in vitro biological assay
like antibacterial activity towards S. pyogens MTCC-442,S. aureus MTCC-
96 and B.subtillis MTCC-441  (Gram positive) and E. coli MTCC-443 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations .i.e.:
0(control), 5, 25, 50, 100, 250 (μg/ml)  for their MIC (Minimum Inhibitory
Concentration) values.The biological activities of the synthesized compounds
(IIIa-j) were compared with standard drugs viz., Amoxicillin, Chlorampheni-
col, Sparfloxacin, Levofloxacin(antibacterial), Griseofluvin, Fluconazole
(antifungal).
  (IIIa-j)
      R=Substituted  phenyl
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF ETHYL-1-N-(2,4-
DINITRO -PHENYL)-6,7,8-SUBSTITUTED-1,4-DIHYDROQUINOLINE-4-
ONE-3-CARBOXYLATES.
(A)     Preparation of Diethyl-(3-chloro-4-fluoro amino phenyl)-
aminomethylene malonate (ld).
For preparation, refer  Part-1, Section-I, page No.30.
(B) Preparation of Ethyl-7-chloro-6-fluoro-1,4-dihydroquinoline-4-
one-3-carboxylate (lId).
For preparation, refer  Part-1, Section-II, page No.58.
(C)     Preparation of Ethyl-1-N-(2,4-dinitro phenyl)-7-chloro-6-fluoro-1,4-
dihydroquinoline-4-one-3-carboxylate ( IIIa-j ).
A reaction mixture of Ethyl-7-chloro-6-fluoro-1,4-dihydroquinoline-4-one-
3-carboxylates (lId)  (2.69 gm, 0.01 M) and anhydrous potassium carbonate
(2.76 gm, 0.02M), in Dimethyl sulphoxide (20 ml) was stirred at  115 to120 OC
for 1 hr. and then allowed to cool upto the temperature 50 to 60 OC. To this
reaction mixture, the solution of 2,4-dinitro chlorobenzene (2.02 gm, 0.01M)
and of dimethyl sulphoxide (6 ml) was added dropwise and the temperature
was maintained at 50 to 60 OC for 8 hrs. The resulting mixture was poured
onto crushed ice, filtered, washed with water and dried at  40 to 45 OC. The
product was crystallized from ethanol. Yield : 64 %, M.P. : 228 OC, (Required :
C,49.61%; H,2.54 %; N, 9.64 %  for C18H11N3O7ClF Found : C, 49.59 %; H,
2.51 %; N, 9.63%).
TLC  solvent system Rf1 : Ethyl acetate : hexane(3.5 : 6.5)  = 0.63.
TLC  solvent system Rf2  : Methanol       : Toluene(1.0 : 9.0) = 0.51.
Similarly, other compounds (IIIa-j) were synthesized. The physical data
are recorded in Table No. 3.
(B) Antimicrobial activity of Ethyl-1-N-(2,4-dinitro phenyl)-(6,7,8-sub-
stituted)-1,4-dihydroquinoline-4-one-3-carboxylates (IIIa-j ).
Antimicrobial activity testing was carried out as described in Part-1(A),
Section-I, page No.30-31. The MIC values of  test solution are recorded in
Table No. 3A, 3B and 3C.
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* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
Part-1(A),  Section-III...,  “Studies on 4-Quinolones”. 90











































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)









































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
Part-1(A),  Section-III...,  “Studies on 4-Quinolones”. 91














































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)









































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
Part-1(A),  Section-III...,  “Studies on 4-Quinolones”. 92











































     -
     -







































Part-1(A),  Section-III...,  “Studies on 4-Quinolones”. 93






































































Part-1(A),  Section-III...,  “Studies on 4-Quinolones”. 94







































     -
     -




































Part-1(A),  Section-III...,  “Studies on 4-Quinolones”. 95





































     -





































































































































































































































































































































































































































































































































































































































































































































































































































































































   
   
   
   











   
   
   
   
   
   
   
   
   
   
   
   
   
   
   











   
   
   
   
   
   























   
   








   
   
   



















































































   
   
   
   


































   
   








   
   
   























































































































































   


















































































































































   
   
   
   
   











   
   
   
   
   
   
   
   
   
   
   
   
   
   
   









   
   








   
   
   














































































   
   
   
   

















































































































   
   








   
   
   














































































































































































































































   
   
   
   












   
   
   
   
   
   
   
   
   
   
   
   
   
   
   










   
   


























































   
   








   
   
   







































   
   






















   
   
   
   





























































































































































































































































Part-1(A),  Section-IV...,  “Studies on 4-Quinolones”. 107
SECTION - IV
PREPARATION AND BIOLOGICAL EVALUATION OF ETHYL-6,7,8-SUB-
STITUTED-1-N-HEPTYL-1,4-DIHYDROQUINOLINE-4-ONE-3-CARBOXY-
LATES.
Keeping in view of various biodynamic activities34-85 of 4-quinolone
and in order to have highly potent therapeutic agents, the synthesis of Ethyl-
1-N-heptyl-6,7,8-substituted-1,4-dihydroquinoline-4-one-3-carboxylates
(IVa-j) have been prepared by the cyclocondensation of different ethyl-sub-
stituted-1,4-dihydroquinoline-4-one-3-carboxylates (IIa-j) and 1-bromo
heptane in the presence of basic condition.
The constitution of the products (IVa-j) have been delineated by elemen-
tal analyses, IR, PMR and Mass spectral data.
The products (IVa-j) were assayed for their in vitro biological assay
like  antibacterial activity towards S. pyogens MTCC-442 ,S. aureus MTCC-
96 and B. subtillis MTCC-441(Gram positive) and E. coli MTCC-443 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations.i.e.:
0(control),5, 25, 50, 100, 250 (μg/ml)  for their MIC (Minimum Inhibitory Con-
centration) values. The biological activities of the synthesized compounds
(IVa-j) were compared with standard drugs viz.,Amoxicillin, Chloramphenicol,







      R=Substituted  phenyl
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF ETHYL-6,7,8-SUB-
STITUTED-1-N-HEPTYL-1,4-DIHYDROQUINOLINE-4-ONE-3-CARBOXY-
LATES.
(A)     Preparation of Diethyl-(3-chloro-4-fluoro amino phenyl)-amino-
methylene malonate (ld).
For preparation, refer Part-1, Section-I, page No.30.
(B) Preparation of Ethyl-7-chloro-6-fluoro-1,4-dihydroquinoline-4-
one-3-carboxylate (lId).
For preparation, refer Part-1,Section-II, page No.58.
(C)     Preparation of Ethyl-1-N-heptyl-7-chloro-6-fluoro-1,4-dihydro
quinoline-4-one-3-carboxylate (IVd).
A mixture of Ethyl-7-chloro-6-fluoro-1,4-dihydroquinoline-4-one-3-
carboxylates(lId).(2.69 gm, 0.01 M) and anhydrous potassium carbonate (2.76
gm, 0.02M), in dimethyl sulphoxide (20 ml) was heated and stirred at 110 to120
OC for 1 hrs. and then allowed to cool up to the temp 60 to70OC. To this reac-
tion mixture, the solution of 1-bromo heptane (1.79 gm, 0.01M) in dimethyl
sulphoxide (6 ml) was added dropwise and the temperature was maintained
95-100OC for 8 hrs.The resulting mixture was poured on to crushed ice, fil-
tered, washed with water and dried. The product was crystallized from etha-
nol. Yield : 47%, M.P. : 46 OC, (Required : C,62.04%; H,6.30 %; N,3.81 %  for
C19H23NO3ClF Found : C, 62.01 %; H, 6.27 %; N, 3.78%).
TLC  solvent system   Rf1 : Ethyl acetate :Hexane        (5.0 : 5.0) = 0.54 .
TLC  solvent system   Rf2 : Methanol        :Chloroform(0.5 : 9.5) = 0.59.
Similarly, other compounds (IVa-j)  were synthesized. The physical data
are recorded in Table No. 4.
(D)  Antimicrobial activity of Ethyl-6,7,8-substituted-1-N-heptyl-substi-
tuted-1,4-dihydroquinoline-4-one-3-carboxylates(IVa-j ).
Antimicrobial activity testing was carried out as described in Part-1(A),
Section-I, page No. 30-31. The MIC values of test solution are recorded in
Table No. 4A, 4B and 4C.
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* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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(IVb)
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(IVd)
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(IVe)
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(IVh)
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(IVd)
































- CH2(n to r)
- CH2(m)
-CH2(b)
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SECTION - V
PREPARATION AND BIOLOGICAL EVALUATION OF SUBSTITUTED-3-[5’-
(2 ’’ ,3 ’’ ,4 ’’ ,5 ’’ -TETRAFLUOROPHENYL)-1’ ,3 ’ ,4 ’ -OXADIAZOL-2’-YL]-
QUINOLONE-4(1H)-ONES.
Keeping in view, various properties34-85of 4-quinolones and in
order to have highly potent therapeutic agents, the synthesis of Substi-
tuted-3-[5’-(2’’,3’’,4’’,5’’-tetrafluorophenyl)-1’,3’,4’-oxadiazol-2’-yl]-
substituted quinolone-4(1H)-ones(Va-j) have been accomplished by
the cyclocondensation of  2,3,4,5-tetrafluoro benzoic acid with differ-
ent  substituted-1,4-dihydroquinoline-4-one-3-carbo hydrazides
which was prepared by the action of hydrazine hydrate on ethyl-sub-
stituted-1,4-dihydroquinoline-4-one-3-carboxylates (IIa-j).
The constitution of the products (Va-j) have been delineated by elemen-
tal analyses, IR, PMR and Mass spectral data.
The products (Va-j)  were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 , S. aureus MTCC-96
and B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations i.e.:
0(control)  5, 25, 50, 100, 250 (μg/ml) for their MIC (Minimum Inhibitory
Concentration) values. The biological activities of the synthesized compounds
(Va-j) were compared with standard drugs,viz.,Amoxicillin, Chlorampheni-











      R=Substituted  phenyl
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF SUBSTITUTED-3-[5’-
(2 ’’ ,3 ’’ ,4 ’’ ,5 ’’ -TETRAFLUOROPHENYL)-1’ ,3 ’ ,4 ’ -OXADIAZOL-2’-YL]-
QUINOLONE-4(1H)-ONES.
(A)     Preparation of Diethyl-(3-chloro-4-fluoro amino phenyl)-amino-
methylene malonate (ld).
For preparation, refer  Part-1, Section-I, page No.30.
(B) Preparation of Ethyl-7-chloro-6-fluoro-1,4-dihydroquinoline-4-
one-3-carboxylate (lId).
For preparation, refer  Part-1, Section-II, page No.58.
(C) Preparation of 7-Chloro-6-fluoro-1,4-dihydroquinoline-4-one-3-
carbohydrazide (5d).
A mixture of Ethyl-7-chloro-6-fluoro-1,4-dihydroquinoline-4-one-3-car-
boxylate (lId) (2.69 gm,0.01M) and hydrazine hydrate 80% (4.0 ml, 0.1 M) in
ethanol (15 ml) and dimethyl formamide (10ml) was heated under reflux for 16
hrs.The excess of the solvent was removed by distillation and reaction mass
was poured in to ice-cold water. The resulting product was filtered, dried and
crystallized from dimethyl formamide. Yield : 74%, M.P. : 233 OC, (Required
:C,46.98 %; H,2.76 %; N,16.44 %  for C10H7N3O2ClF, Found : C, 46.93 %;
H,2.72 %; N,16.39 % ).
TLC solvent system   Rf1 : Ethyl acetate : Hexane(5.5 : 4.5)  = 0.43.
TLC  solvent system  Rf2 :  Methanol       : Toluene(4.0 : 6.0) = 0.51 .
Similarly, other compounds (5a-j) were synthesized. The physical data
are recorded in Table No.5.
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(D)     Preparation of 7-chloro-6-fluoro-3-[5’-(2’’,3’’,4’’,5’’-tetra fluoro-
phenyl)-1’,3’,4’-oxadiazol-2’-yl]- quinolone-4(1H)-one (Vd).
A mixture of  7-chloro-6- f luoro-1,4-d ihydroquinol ine-4-one-3-
carbohydrazide (5d) (2.55 gm, 0.01 M) and 2,3,4,5- tetrafluoro benzoic acid
(1.94 gm, 0.01M) in phosphorus oxychloride (15 ml) was  heated under reflux
for 6 to 7 hrs. The reaction was monitored by TLC. After completion of reac-
tion, the reaction mixture was poured on to crushed ice. The reaction mixture
was neutralized with solution of 10% sodium bicarbonate. The resulting solid
mass (brown red color precipitates) was filtered, washed with water, dried
and  crystallized from ethanol. Yield : 67 %, M.P. : 134 OC, (Required : C, 49.3
%; H, 1.22 %; N,10.16 %  for C17H5N3O2ClF5, Found : C, 49.0 %; H, 1.18 %;
N,10.12 %).
TLC  solvent system  Rf1: Ethyl acetate :Hexane(2.0 : 8.0)  = 0.54.
TLC  solvent system  Rf2: Methanol        :Toluene(0.5 : 9.5) = 0.59.
Similarly, other compounds ( Va-j )  were synthesized. The physical data
are recorded in Table No. 5A.
(E) Antimicrobial activity of Substituted-3-[5’-(2’’,3’’,4’’,5’’-tetra -
fluoro phenyl)-1’,3’,4’-oxadiazol-2’-yl]-quinolone-4(1H)-ones (Va-j).
Antimicrobial activity testing was carried out as described in Part-1(A),
Section-I, page No. 30-31. The MIC values of test solution are recorded in
Table No. 5B, 5C and 5D.
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C-N (str., v)
C=N (str., v)





C-O-C (sym. str., s)
C-F (str., b)




























































































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C-N (str., v)
C=N (str., v)















































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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(Vc)












































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C-N (str., v)
C=N (str., v)














































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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(Vd)














































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C-N (str., v)
C=N (str., v)














































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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(Vb)
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(Vc)
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(Vd)
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SECTION - VI
PREPARATION AND BIOLOGICAL EVALUATION OF 3-[4’-AMINO-5 ’ -
(2 ’’ ,3 ’’ ,4 ’’ ,5 ’ ’ -TETRA FLUORO PHENYL)-4H-1’ ,2 ’ ,4 ’ -TRIAZOL-3’-YL]-
SUBSTITUTED-QUINOLONE-4(1H)-ONES.
Keeping in view, various properties34-85 of 4-quinolones and in
order to have highly potent therapeutic agents, the synthesis of 3-[4’-
amino-5’-(2’’,3’’,4’’,5’’-tetrafluorophenyl)-4H-1’,2’,4’-triazol-3’-yl]-
Substituted-quinolone-4-(1H)-ones (VIa-j) have been accomplished by
the cyclocondensation of di fferent substituted-3-[5’-(2’’ ,3’’ ,4’’ ,5’’-
tetrafluorophenyl)-1’,3’,4’-oxadiazol-2’-yl]- quinolone-4-(1H)-ones (Va-j)
and hydrazine hydrate.
The constitution of the products  (VIa-j)  have been delineated by elemen-
tal analyses, IR, PMR and Mass spectral data.
The products (VIa-j)  were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442, S. aureus MTCC-96
and B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443 (Gram
negative) bacterial strains and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations i.e.:
0(control), 5, 25, 50, 100, 250 (μg/ml) , for their MIC (Minimum Inhibitory  Con-
centration) values. The biological activities of the synthesized compounds
(VIa-j) were compared with standard drugs,viz., Amoxicillin, Chlorampheni-












      R=Substituted  phenyl
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 3-[4’-AMINO- 5 ’ -
(2 ’’ ,3 ’’ ,4 ’’ ,5 ’’ -TETRAFLUOROPHENYL)-4H-1 ’ ,2 ’ ,4 ’ -TRIAZOL-3’-YL]-
SUBSTITUTED-QUINOLONE-4(1H)-ONES.
(A)     Preparation of Diethyl-(3-chloro-4-fluoro amino phenyl)-amino-
methylene malonate (ld).
For preparation, refer  Part-1, Section-I, page No. 30.
(B) Preparation of Ethyl-7-chloro-6-fluoro-1,4-dihydroquinoline-4-
one-3-carboxylate (lId).
For preparation, refer  Part-1, Section-II, page No.58.
(C) Preparation of 7-chloro-6-fluoro-1,4-dihydroquinoline-4-one-3-
carbohydrazide (5d).
For preparation, refer  Part-1, Section-V, page No.137.
(D)     Preparation of  3-[5’-(2’’,3’’,4’’,5’’-tetrafluorophenyl)-1’,3’,4’-
oxadiazol-2’-yl]-7-chloro-6-fluoroquinolone-4(1H)-one (Vd ).
For preparation, refer  Part-1, Section-V, page No.138.
(E)     Preparation of  3-[4’-amino-5’-(2’’,3’’,4’’,5’’-tetrafluorophenyl)-4H-
1’,2’,4’-triazol-3’-yl]- 7-chloro-6-fluoro-quinolone-4-(1H)-one (VId).
A mixture of 7-chloro-6-fluoro-3-[5’-(2’’,3’’,4’’,5’’-tetrafluoro phenyl)-
1’,3’,4’-oxadiazol-2’-yl]-7-chloro-6-fluoro-quinolone-4(1H)-one (VId) (2.55 gm,
0.01 M) in hydrazine hydrade 80 % (10 ml) was heated under reflux for 8 hrs.The
reaction mass was allowed to cool at  room temperature. The reaction mixture
was poured on to crushed ice. The reaction mixture was neutralized with gl.
acetic acid. The reaction mixture was filtered, washed with water and recrys-
tallized from ethanol. Yield : 43 %, M.P.: 297 OC, (Required : C, 47.74 %; H,1.65
%; N,16.37 %  for C17H7N5OClF5, Found : C, 47.70 %; H,1.61 %; N,16.32
%.
TLC  solvent system  Rf1 : Ethyl acetate : Hexane(2.5 : 7.5) = 0.49.
TLC  solvent system  Rf2 : Methanol        : Toluene(1.0 : 9.0) = 0.42.
.
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Similarly, other compounds (VIa-j) were synthesized. The physical data
are recorded in Table No.6.
(F) Antimicrobial activity of 3-[4’-amino-5’-(2’’,3’’,4’’,5’’-tetra fluoro-
phenyl)-4H-1’,2’,4’-triazol-3’-yl]-Substituted-quinolone-4-(1H)-ones
(VIa-j).
Antimicrobial activity testing was carried out as described in Part-1(A),
Section-I, page No. 30-31. The MIC values of test solution are recorded in
Table No. 6A, 6B and 6C.
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IR  SPECTRAL STUDY OF 3- [4 ’ -AMINO-5’ - (2 ’ ’ ,3 ’’ ,4 ’’ ,5 ’’ -TETRA-
F L U O R O P H E N Y L ) - 4 H - 1 ’ , 2 ’ , 4 ’ - T R I A Z O L - 3 ’ - Y L ] - 6 - F L U O R O -









































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C-N (str., v)
C=N (str., v)
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(VIb)











































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C-N (str., v)
C=N (str., v)








































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C-N (str., v)
C=N (str., v)








































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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(VIi)











































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C-N (str., v)
C=N (str., v)





































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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(VIb)
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NMR SPECTRAL STUDY OF 3-[4’-AMINO-5’-(2’’ ,3’’ ,4’’ ,5’’ -TETRA-



















































































































































































































































































































































































































m/z= 221.5(M+2),  C11H8ClN3O
m/z= 235.5(M+1),
 C10H7ClN2O
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SECTION - VII
PREPARATION AND BIOLOGICAL EVALUATION OF-3-[1’-N-AMINO-2’-
MERCAPTO-1’,3’,4’-TRIAZOL-5’-YL)-SUBSTITUTED-QUINOLONE-4-(1H)-
ONES.
Keeping in view, various biological properties34-85 of 4-quinolones
and in order to have highly potent therapeutic agents, the synthesis of 3-[1’-N-
amino-2’-mercapto-1’,3’,4’-triazol-5’-yl)-Substituted-quinolone-4-(1H)-
ones (VIIa-j). have been accomplished by the cyclocondensation of different
substituted 1,4-dihydroquinoline-4-one-3-carbohydrazides (5a-j), car-
bon disulphide and pottassium hydroxide followed by the action of hydra-
zine hydrate.
                                                                      (VIIa-j)
      R=Substituted  phenyl
The constitution of the products (VIIa-j) have been delineated by elemental
analyses, IR, PMR and Mass spectral data.
The products (VIIa-j) were assayed for their in vitro biological assay
like  antibacterial activity towards S. pyogens MTCC-442 , S. aureus MTCC-
96 and B. subtillis MTCC-441(Gram positive) and E. coli MTCC-443 (Gram
negative) bacterial strains and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations i.e.
:0(control), 5, 25, 50,100, 250 (μg/ml), for their MIC (Minimum Inhibitory
Concentration) values. The biological activities of the synthesized compounds
(VIIa-j) were compared with standard drugs,viz., Amoxicillin, Chlorampheni-



























 (1) KOH, CS2
 (2) NH2-NH2 2H2O
 (VIIa-j) 
R= substituted phenyl
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF SUBSTITUTED--3-
[1’-N-AMINO-2’-MERCAPTO-1’,3’,4’-TRIAZOL-5’-YL)-QUINOLONE-4-(1H)-
ONES.
(A)     Preparation of  Diethyl-(3-chloro-4-fluoro amino phenyl)- amino
methylene malonate (ld).
For preparation, refer Part-1,Section-I, page No. 30.
(B) Preparation of Ethyl-7-chloro-6-fluoro-1,4-dihydroquinoline-4-
one-3-carboxylate (lId).
For preparation, refer Part-1,Section-II, page No.58.
(C) Preparation of 7-chloro-6-fluoro-1,4-dihydroquinoline-4-one-3-
carbohydrazide (5d).
For preparation, refer Part-1,Section-V, page No.137.
(D)     Preparation of 7-chloro-6-fluoro-3-[1’-N-amino-2’-mercapto-
1’,3’,4’ -triazol-5’-yl)-quinolone-4-(1H)-one (VIId).
 A mixture of  7-chloro-6-f luoro-1,4-dihydroquinol ine-4-one-3-
carbohydrazide (5d) (2.55 gm, 0.01 M) and KOH (0.84 gm, 0.015 M) in abso-
lute ethanol (30 ml), was stirred at 35 to 40 OC. Carbon disulphide (1.52 ml,
0.02 M) was added in to the reaction mixture within 30 minutes under stirring.
The reaction mixture was then stirred at room tempreture for 8 hrs. under
anhydrus condition. The white solid mass (dithiocarbamate) seprated out, which
was filtered, washed with ethanol and dried.
This dithiocarbamate was dissolved in water (25 ml) and hydrazine hy-
drate (80%) (3.9 ml 0.1mol) was added to the resulting solution with stirring.
The reaction mixture was heated under reflux for 8 hrs.The reaction mass was
then allowed to cool at  35 to 40 OC  and poured  in to crushed ice. The pH was
then adjusted between 5.5 to 6.5 by acidifying the mixture with Conc. hydro
chloric acid at the temperature 0-5 OC. The creamish white solid so obtained
was filtered, washed with water and recrystallized from dimethyl formamide.
Yield : 85 %, M.P.: 289OC, (Required : C, 42.38 %; H, 2.26 %; N, 22.47 %  for
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C11H7N5OSClF, Found : C, 42.32 %; H, 2.24 %; N, 22.42%).
TLC  solvent system  Rf1: Ethyl acetate : Hexane(4.0 : 6.0)  = 0.57.
TLC  solvent system  Rf2: Methanol        : Toluene(1.5 : 8.5) = 0.52.
Similarly, other compounds (VIIa-j) were synthesized. The physical data
are recorded in Table No. 7.
(E) Antimicrobial activity of Substituted-3-[1’-N-amino-2’-mercapto-
1’,3’,4’-triazol-5’-yl)-quinolone-4-(1H)-ones (VIIa-j).
Antimicrobial activity testing was carried out as described in Part-1(A),
Section-I, page No. 30-31. The MIC values of test solution are recorded in
Table No. 7A, 7B, and 7C.
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (o.o.p. def., m)
C-N (str., v)
C=N (str., v)
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(VIIc)









































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (o.o.p. def., m)
C-N (str., v)
C=N (str., v)









































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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(VIId)











































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C-N (str., v)
C=N (str., v)











































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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(VIIh)







































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C-N (str., v)
C=N (str., v)




































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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(VIIi)







































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (o.o.p. def., m)
C-N (str., v)
C=N (str., v)


































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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(VIIc)
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(VIId)


















































Part-1(A),  Section-VII...,  “Studies on 4-Quinolones”. 198
(VIIh)
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(VIIi)
































     -




























































































































































































































































































































































































































































































































































































































































































m/z= 200(M+2),  C12H11N3O
m/z= 213(M+1),
 C8H9NO
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SECTION - VIII
PREPARATION AND BIOLOGICAL EVALUATION OF SUBSTITUTED-3-
[6’-(2’’,3’’,4’’,5’’-TETRAFLUOROPHENYL)(1’,2,’,4’)-TRIAZOLO-(3’,a-
b)[1’,3’,4’]-THIADIAZOLE-3-YL]-QUINOLONE-4(1H)-ONES.
Keeping in view, various biological properties34-85 of 4-quinolone  and
in order to have highly potent therapeutic agents, the synthesis of  Substi-
tuted-3-[6’-(2’’,3’’,4’’,5’’,-tetrafluoro phenyl)(1’,2,’,4’)-triazolo-(3’,a-
b)[1’,3’,4’]-thiadiazole-3-yl]-quinolone-4(1H)-ones (VIIIa-j) have been ac-
complished by the cyclocondensation of different substituted-3-[1’-N-amino-
2’-mercapto-1’,3’,4’-triazol-5’-yl)-quinolone-4-(1H)-ones (VIIa-j) and
2,3,4,5-tetrafluoro benzoic acid in the presence of phosphorous oxychlo-
ride.
The constitution of the products (VIIIa-j)  have been delineated by elemen-
tal analyses,IR, PMR and Mass spectral data.
The products (VIIIa-j)   were assayed for their in vitro biological assay
like  antibacterial activity towards S.pyogens MTCC-442 , S.aureus MTCC-
96 and B.subtillis MTCC-441 (Gram positive) and  E. coli MTCC-443 (Gram
negative) bacterial strains and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrationsi.e.
:0(control), 5, 25, 50, 100, 250 (μg/ml)  for their MIC (Minimum Inhibitory
Concentration) values. The biological activities of the synthesized compounds
(VIIIa-j) were compared with standard drugs viz., Amoxicillin, Chlorampheni-














      R=Substituted  phenyl
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL SCREENING OF SUBSTITUTED-3-[6’-
(2’’ ,3’’ ,4’’ ,5’’ , -TETRAFLUOROPHENYL)(1 ’,2, ’ ,4’ ) -TRIAZOLO-(3’ ,a-
b)[1’,3’,4’]-THIADIAZOLE-3-YL]-QUINOLONE-4(1H)-ONES.
(A)     Preparation of  Diethyl-(3-chloro-4-fluoro amino phenyl)-amino-
methylene malonate (ld).
For preparation, refer Part-1,Section-I, page No.30.
(B) Preparation of Ethyl-7-chloro-6-fluoro-1,4-dihydroquinoline-4-
one-3-carboxylate (lId).
For preparation, refer Part-1, Section-II, page No.58.
(C) Preparation of 7-chloro-6-fluoro-1,4-dihydroquinoline-4-one-3-
carbohydrazide (5d).
For preparation, refer Part-1, Section-V, page No.137.
(D)     Preparation of  7-chloro-6-fluoro-3-[1’-N-amino-2’-mercapto-1’,3’-
4’-triazol-5’-yl)-quinolone-4-(1H)-one (VIId).
For preparation, refer Part-1, Section-VII, page No.187.
(E)     Preparation of  7-chloro-6-fluoro-3-[6’-(2’’,3’’,4’’,5’’,-tetrafluorophen
yl)(1’,2,’,4’)-triazolo-(3’,a-b)[1’,3’,4’]-thiadiazole-3-yl]-quinolone-4(1H)-
one (VIIId).
A mixture of 7-chloro-6-fluoro-3-[1’-N-amino-2’-mercapto-1’,3’,4’-triazol-
5’-yl)-quinolone-4-(1H)-one (VIId) (3.11gm,0.01 M) and 2,3,4,5-tetra fluoro ben-
zoic acid (1.94 gm,0.01M) in phosphourus oxychloride (15 ml) was heated
under reflux for 8 hrs. The rection was monitored by  TLC. After the completion
of reaction, the reaction mixture was allowed to cool at room temprature and
then poured on to crushed ice. The pH was then adjusted to neutral by dropwise
addition of 10% sodium bicarbonate solution. The brown red colour precipi-
tates so obtained was filtered, washed with water, dried.The product was crys-
tallized from ethanol. Yield : 65 %, M.P. : 83 OC, (Required : C, 46.02 %; H,
1.07 %; N,14.91 %  for C18H5N5OSClF5, Found :  C, 45.98 %; H, 1.02 %;
N,14. 88%).
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TLC solvent system  Rf1 : Ethyl acetate : Hexane       (2.0 : 8.0) = 0.57.TLC  solvent system Rf2 : Methanol        : Chloroform(0.5 : 9.5  = 0.52.
Similarly, other compounds (VIIIa-j)  were synthesized. The physical data
are recorded in Table No. 8.
(B) Antimicrobial activity of Substituted-3-[6’-(2’’,3’’,4’’,5’’,-tetrafluoro
phenyl)(1’,2,’,4’)-triazolo-(3’,a-b)[1’,3’,4’]-thiadiazole-3-yl]-quinolone-
4(1H)-ones (VIIIa-j)
Antimicrobial activity testing was carried out as described in Part-1(A),
Section-I, page No. 30-31.The MIC values of test solution are recorded in Table
No. 8A, 8B and 8C.
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (o.o.p. def., m)
C-H (i.p. def., m)
C-N (str., v)
C=N (str., v)








































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.


















































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-N (str., v)
C=N (str., v)









































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
Part-1(A), Section-VIII..., “Studies on 4-Quinolones”. 220
(VIIIc)

















































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (o.o.p. def., m)
C-H (i.p. def., m)
C-N (str., v)
C=N (str., v)
N-N  (def., v)
C-S-C(str.m)
N-H (str., b)









































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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(VIIId)
IR SPECTRAL STUDY OF 7-CHLORO-6-FLUORO-3-[6’-(2’’,3’’,4’’,5’’,-

















































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (o.o.p. def., m)
C-H (i.p. def., m)
C-N (str., v)
C=N (str., v)











































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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(VIIIe)


















































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (o.o.p. def., m)
C-H (i.p. def., m)
C-N (str., v)
C=N (str., v)











































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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(VIIIb)
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(VIIIc)
NMR SPECTRAL STUDY OF 6-CHLORO-3-[6’-(2’’,3’’,4’’,5’’,-TETRA-
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(VIIId)
NMR SPECTRAL STUDY OF 7-CHLORO-6-FLUORO-3-[6’-(2’’,3’’,4’’,5’’,-
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PART - I(B)
STUDIES ON PYRIMIDO[2,1-b] [1,3] BENZOTHIAZOLE
-4-ONES
INTRODUCTION:
Thiazole is a five membered heterocyclic ring system having sulfur and
nitrogen as heteroatoms.The benzthiazole ring system bears phenyl ring fused










The history of the true thiazole series begins in 1879 with the work of
Hof fmann,  who prepared der ivat ives o f  benzth iazo le  such as 2-
chlorobenzthiazole.2-phenylbenzthiazole100 containing the thiazole nucleus
were first reported by Hantzsh et.al., in a series of papers begining in 1887101.
Pyrimidine (18) is a six membered heterocyclic compound consisting





Generally pyrimidine derivatives such as 2-hydroxy-substituted-pyrimidines,
2-mercapto-substituted-pyrimidines and 2-amino-substituted-pyrimidines were
studied. Pyrimidines have been isolated from the nucleic acid hydrolysates.
Pyrimidines are among those molecules that make life possible, have
been some of the building blocks of DNA and RNA. Several analogues of
pyrimidines have been used as compounds that interfere with the synthesis
and functioning of nucleic acids e.g. fluorouracil, which has been used in can-
cer treatment. Also there are some thiouracil derivatives, which produce ad-
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verse reduction in susceptible patients and found more potent and less likely
to produce side effects and is being widely used102. There are several other
important groups of pyrimidines with medicinal uses.
SYNTHETIC ASPECT OF BENZTHIAZOLE :
(A) By the condesation of  o-amino thiophenol with a carboxylic acid or
its derivatives or an aldehyde103-114.
(B) By the Cyclisation of Benzenecarbothiaoamide  in aqueous alkali with
potassium ferricyaninde to give 2,3-dihydrobenz thiazoles115-117.
(C) By the spontaneous Cyclisation of o-thiocyanato arylamines  to pro
duce 2-aminobenzthiazoles with good  yields118-119.
(D) By the Condensation of o-aminothiaphenol reacts with aromatic 1,2-
diketones in boiling methanol yielding 2-aroyl-2-arylbenzothiazolines
         on boiling in acetic acid affords corresponding 2-arylbenzothiazole120
(E) By the Condensation of arylthiourea liquid bromine in chloroform to
affords 2-aminobenzothioazole121.
(F) By the Cyclisation of o-Nitroaryl thiocyantes to 2-aminobenzothia-
zole122.
SYNTHETIC METHODS FOR PYRIMIDINES
Various methods for synthesis of pyrimidines  which are reported in the
literature are as follows.
(a) By the condensation of urea and malonic acid led to formation of pyrimidine123.
(b) By the condensation of malonic ester and urea led to formation of pyrimidine124.
(c) By the condensation of formamidine with phenylazomalononitrile led to
formation of 4,5,6-triaminopyrimidine125.
(d) By the condensation of aromatic aldehydes,ß-ketoester or substituted
ß-ketoester with urea or thiourea led to formation of pyrimidines126.
(e) By the condensation of thiourea and substituted ß-ketoester in pres
ence of sodium ethoxide led to formation of 2-mercaptopyrimidines127.
(f) By the condensation of chalcones with dicyandiamide in presence of
piperidine led to formation of pyrimidines128.
(g) By thermal or microwave irridiation of thiourea and substituted ß-ketoester
in presence of dimethylformamide led to formation of substituted
tetrahydropyrimidines129.
Part-1(B),  Introduction...,  “Studies on pyrimido[2,1-b][1,3]benzothiazole-4-ones”. 245
(h) One pot synthesis of aromatic aldehydes,ß-ketoester or substituted
ß-ketoester with urea or thiourea led to formation of substi tuted
dihydro pyrimidin-2-ones catalysed by CuCl2130.
(i) One pot synthesis of aromatic aldehydes,ß-ketoester or substituted
ß-ketoester with urea or thiourea led to formation of 3,4-dihydro
pyrimidin-2-(1H)-ones/thiones under microwave irradiation131.
(j) One pot synthesis of aromatic aldehydes,ß-ketoester or substituted
ß-ketoester  wi th  urea or  th iourea led to  format ion of  d ihydro
pyrimidin-2-(1H)- ones catalysed by Tin (II) chloride (SnCl2)131.
(k) One pot synthesis of aromatic aldehydes,ß-ketoester or substituted
ß-ketoester with urea or thiourea led to formation of  3,4-dihydro
pyrimidin-2-(1H)-ones by microwave induced eco-friendly solvent free
biginelli reaction catalysed by calcium chloride132.
MEDICINAL INTEREST OF BENZOTHIAZOLE :-
Some well known drugs which are having benzthiazole nucleus.












(Drug for glucoma and macular Antiglutamate" Anticonvulsant"
Literature survey revealed that various benzthiazoles have resulted in
many potential drugs and are known to exhibit a broad spectrum of thera-
peutic activities such as   :





[F]      Antimicrobialactivity143-144
[G] Analgesic,Antipyretic activity145.
[H] Pesticidal146.
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MEDICINAL INTEREST OF PYRIMIDINES
In medicinal chemistry, pyrimidine derivatives have been very well
known for their therapeutic applications. The presence of pyrimidine base in
the thymine, cytosine and uracil, which are the essential building blocks of
nucleic acids, DNA and RNA is one possible reason for their activity. The
literature indicates the compounds having pyrimidine nucleus possess broad
range of biological activities, like 5-fluorouracil as anticancer; idoxuridines
and tr i f luoridine as antiviral;  zidovudine and stavudine as antiHIV;
tr imethoprim, sulphamethazine and sulphadiazine as ant ibacter ial ;
sulphadoxin as antimalarial and antibacterial; minoxidil and prazosin as an-
tihypertensive; barbiturates eg. phenobarbitone as sedative, hypnotics and
anticonvulsant; propylthiouracil as antithyroid; thionzylamine as H1-antihista-
mine; and toxoflavin and fervennuline as antibiotics.




[C]     Antihypertensive178-180
[D]     Antiinflammatory1181-183
[E]      Diuretic184
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[F] Antimalarial185-187
[G]     Antispasmodic188
[H]     Anticonvulsant189
[I] Antineoplastic190
[J]      Anthelmintic191
[K]     Cardiovascular192-194
[L] Antitubercular195
[M]     Antiviral196-197
[N]     Antihistamine198
[O]     Anti-HIV199-200
[P]     Antimicrobial201-220
L. raeane et.al.,221.  have prepared benzthiazole derivatives (19) and
(20), which have been found to possess Anti HIV activity. J. Hofmann et. al.,150.























X=S,N,O, Het= Quinolinyl, Isoquinolinyl, 2-Pyridyl
Recently, K.Thomas et.al.,222. have synthesised benzthiazole deriva-
tives of type(22) as antihelicobacterpylori agent.
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R.J.Alamino et. al.,223-224 have synthesized a series of thiocynato
benzothiazole, as a novel antiparasitic agents. The anthelmintic activity of the
compound (23) was determined against as carissuum and hymenolepisnana
in the mouse, and the result of the testing the activity data of (23) against
these two helminthes failed to establish any structure-activity relationships.
only compound 6-ethyl-2-aminobenzothiazole (24) had comparable activity to













The antifungal activity of (23) was determined in sabourauds liquid me-
dium BBL and the MIC values  were tested against a number of yeast species.
The most active compound tested were (25) and (26) and in addition, both
significantly inhibited the growth of Candida albicans and micros Porum conis
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    The vitamin, thiamine is the only natural product  found to posses
the thiazole nucleus227.Sulfathiazole, the most potent sulfa drug in general
use and promizol  (4-aminophenyl-2-aminothiazoly l -5-sul fone)228a
tuberculotherapeutic agent, are among the best-known thiazoles used in
present-day medicine. The versatility of the thiazole is further demonstrated
by the fact that some of these compounds possess antimalarial activity229
that 2-(4-thiazolyl)-ethylamine has biological properties similar to those of
histamine230 and that 2-aminothiazole exhibits antithyroid activity231.
2-amino-6-carboxy benzothiazole (28), is parent scaffold  of the
two well known local anesthetics, procaine (27) and butyn (29).

















P. Khalili et. al.,232 have carried out biochemical and pharmacokinetic
evaluation of a novel nitric oxide donor pyrimidine nucleoside hybrid drug as a
potential anticancer / antiviral agent. Rostom S.A.et al.,233 have synthesized and
screened certain 2-(benzoxazol-2-yl-amino)-3H-4-oxopyrimidines for in vitro
anti-HIV activity.
A family of trisubstituted pyrimidines has been described as selective
COX-2 inhibitors. To explore the usefulness of pyrimidine derivatives as potential
NSAIDs, A. Orjales et. al.,234 have synthesized novel pyrimidine derivatives
(30) and (31). In vitro biological evaluation of these compounds has provided
information to determine the structural features necessary for COX-2 inhibitory
activity.
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(30) Y = CH; X, Z = N      (31)  Y, Z = N; X = CH
D.Rot i l i  e t  a l . ,235  have  syn thes ized  6 -subs t i tu ted- [1 - (2 ,6 -
difluorophenyl]pyrimidinones (32,33) and tested against endogenous,
nontelomeric reverse transcriptase (endo-RT) in human differentiating cell


















R. Stoorer et al.,236 have synthesized 3-substituted-6-(3-ethyl-4-
methylanilino)uracils (34,35) screened for their capacity to inhibit the replica-
tion-specific bacterial DNA plymerase IIIC (pol IIIC) and the growth of Gram+
bacteria in culture.
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A.Or ja les  e t  a l . ,237  have  syn thes ized  new ser ies  o f  2 - (4 -
methylsulfonylphenyl) and 2-(4-sulfamoylphenyl) pyrimidines (36) and evalu-









After persuing exostive literature survey it was found that not attempt
was made to synthesis fused benzthiazole with any heterocycles moities and
evaluated for biological profile.
This part includes the synthesis and biological studies in benzthiaozole
is fused with pyrimidine and its biological activity is evaluated which can be
summarized in the following section.
SECTION - I :        PREPARATION AND BIOLOGICAL EVALUATION OF
7 ,8 ,9 -ETHYL-SUBST ITUTED-10a -D IHYDRO-4H-PYRIMIDO[2 ,1 -
b][1,3]BENZOTHIAZOLE-4-ONE-3-CARBOXYLATES.
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SECTION - I
PREPARATION AND BIOLOGICAL EVALUATION OF ETHYL-7,8,9-SUB-
STITUTED-10a-DIHYDRO-4H-PYRIMIDO[2,1-b][1,3]BENZOTHIAZOLE-4-
ONE-3-CARBOXYLATES.
Keeping in view of various biodynamic activities133-220 of pyrimido[2,1-
b] [1,3] benzothiazole-4-ones and in order to have highly potent therapeutic
agents, the synthesis of Ethyl-7,8,9-substituted-10a-dihydro-4H-
pyrimido[2,1-b][1,3]benzothiazole-4-one-3-carboxylates (IXa-j) have been
accomplished by the condensation of different-4,5,6-substituted 2-amino
benzothiazoles and diethyl ethoxy methylene malonate.
The constitution of the products (IXa-j)  have been delineated by elemen-
tal analyses, IR, PMR and Mass spectral data.
The products (IXa-j)  were assayed for their in vitro biological assay
like  antibacterial activity towards S. pyogens MTCC-442 , S. aureus MTCC-
96,and B. subtillis MTCC-441 (Gram positive) and E. coli MTCC-443 (Gram
negative) bacterial strains and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations
i.e.:0(control), 5, 25, 50, 100, 250 (μg/ml) for their MIC (Minimum Inhibitory
Concentration) values. The biological activities of the synthesized compounds
(IXa-j) were compared with standard drugs,,viz. Amoxicillin, Chlorampheni-









      R=Substituted  phenyl

































 methylene malonate 
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF ETHYL-7,8,9-SUB-
STITUTED-10a-DIHYDRO-4H-PYRIMIDO[2,1-b][1,3]BENZOTHIAZOLE-4-
ONE-3-CARBOXYLATES.
(A) Preparation of 4,5,6-substituted- 2-amino-1,3- benzothiazole.
 For preparation, of 4,5,6-substituted- 2-amino-1,3- benzothiazole re-
fer in literature121,
(B) Preparation of diethyl {[(6-methoxy-1,3-benzothiazol-2-yl)amino] me-
thylene} malonate (9a-j).
A mixture of 6-methoxy- 2-amino-1,3- benzothiazole (1.80 gm, 0.01 M),
and diethyl ethoxy methylene malonate (1.06 ml, 0.01M) in  ethanol (20ml) was
heated under reflux for 4 hrs. The rection mixture was then allowed to cool at
0 to 5 OC  temperature. The rection mixture was poured in to ice-water, fil-
tered, washed with water, dried and recrystallized from ethanol:water (3:1).
Yield : 52 %, M.P.: 89 OC,(Required : C, 54.85 %; H, 5.18 %; N, 7.99 %  for
C16H18N2O5S, Found : C, 54.81 %; H, 5.12 %; N, 7.92 %).
TLC  solvent system  Rf1 : Ethyl acetate : Hexane(1.0 : 9.0)  = 0.59.
TLC  solvent system  Rf2 : Methanol        : Toluene(1.5 : 8.5) = 0.56.
Similarly, other compounds (9a-j) were synthesized. The physical data
are recorded in Table No.9.
(C) Preparation of Ethyl 8-methoxy-10a-dihydro-4H-pyrimido[2,1-
b][1,3]benzothiazole-4-one-3-carboxylate (IXa-j).
A mixture of diethyl {[(6-methoxy-1,3-benzothiazole-2-yl)amino] methylene}
malonate (3.50gm, 0.01 M) in dimethyl sulphoxide(20 ml) was heated with stir-
ring and the reaction mixture was then refluxed for 8 hrs. The resulting mixture
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was allowed to cool at room temperature. The reaction mixture was poured in
ice-cold water, filtered, washed with water and crystallized from Dimethyl
formamide. The product was dried at 45-50 OC. Yield : 45 %, M.P. : 189 OC,
(Required : C, 54.89 %; H, 4.61 %; N, 9.14 %  for C14H14N2O4S, Found : C,
54.83 %; H, 4.58 %; N, 9.10 %).
TLC  solvent system  Rf1 : Ethyl acetate : Hexane (3.0 : 7.0) =  0.51.
TLC  solvent system  Rf2 : Methanol        : Toluene (1.0 : 9.0) = 0.38.
Similarly, other compounds (IXa-j) were synthesized. The physical data
are recorded in Table No.9A.
(D) Antimicrobial activity of Ethyl-7,8,9-substituted-10a-dihydro-4H-
pyri mido[2,1-b][1,3]benzothiazole-4-one-3-carboxylates (IXa-j) .
Antimicrobial activity testing was carried out as described in Part-1(A),
Section-I, page No.30-31. The MIC values of test solution are recorded in Table
No.9B, 9C and 9D.
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)

























* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
(IXa)
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(IXb)








































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)







































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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(IXd)
IR SPECTRAL STUDY OF ETHYL-7-CHLORO-8-FLUORO-10a-DI-










































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)










































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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(IXf)
IR SPECTRAL STUDY OF ETHYL-8-NITRO-10a-DIHYDRO-4H-PYRI-












































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)









































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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(IXh)




































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C=C & C-C (str., v)
































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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(IXa)
NMR SPECTRAL STUDY OF ETHYL-8-FLUORO-10a-DIHYDRO-4H-PYR-
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(IXb)
NMR SPECTRAL STUDY OF ETHYL-7-CHLORO-10a-DIHYDRO-4H-PYR-
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(IXd)
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(IXg)
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PART - II
STUDIES ON 1,4-DIHYDROPYRIDINE DERIVATIVES
INTRODUCTION
In 1,4-dihydropyridine structure either imino (NH) or substituted nitro-
gen atom is present at the  one position and hydrogen atom at the four posi-
tion of the six membered heterocyclic ring which can be represented as under
(37).
    R1, R4  = H / Alkyl / Aryl
                  R2, R6  = Methyl, Isopropyl
                                                        R3, R5  =  Acetyl /Carbmethoxy/
             Carbethoxy / N-Aryl Carbamoyl
1,4-dihydropyridines contribute as an important class of compounds
in medicinal chemistry, leading to several new drugs currently  widely used espe-
cially as calcium channel antagonist238 and other cardiovascular diseases
also.  .
SYNTHETIC METHODS OF DIHYDROPYRIDINE
B. Chekavichus et.al.,239  has proposed following kind of successive
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The synthesis of 1,4-dihydropyridines involves following steps.
(1) Intermediate (A) involves cyclisation of 3-arylaminocrotonate and arylidene
followed by the rearrangement of hydrogen.
(2) Intermediate (B) involves dehydration of (A) with loss of equimolar quan
tity of water.
(3) Intermediate (C) involves isomerisation of intermediate of (B) and obt
ained regio and stereo selective 1,4-dihydropyridine as a final product.
It has been observed that in the presence of piperidine as a catalyst,
pyran was formed as an intermediate by the cyclocondensation of aliphatic or
aromatic aldehydes with 1,3-diketones, followed by the dehydration of pyran
through the reaction with aliphatic or aromatic amines affored final product.

































       R, R3 = H / Aryl / Aryl
R1, R2 = Carboxylate/ Arylcarbamoyl
MECHANISM


































































(1) Abstraction of proton by base from ethyl acetoacetate form nucleophile.
(2) Attack of nucleophile on aldehyde molecule to yield bis-keto ester.
(3) Condensation of NH3 with bis-keto ester with removel of water molecule
to give 1,4-dihydropyridine derivative.
SYNTHETIC METHODS OF 1,4-DIHYDROPYRIDINES
Different synthetic methods for the synthesis of 1,4-dihydropyridines
are as follows.
(1) By the condensation of aromatic or aliphatic aldehydes with acetoacet-
icester and aromatic / aliphatic amine in presence of pyridine 240-243.
(2) By the condensat ion of  a l iphat ic or  aromat ic a ldehydes wi th 3-
amino crotonate and 1,3-diketone 239,244-250.
(3) By the condensation of arylidene with 3-aminocrotonate251.
(4) By the condensation of aliphatic or aromatic aldehydes with various
1,3-diketones in presence of ammonia or ammonium carbonate252-
254.
(5)       By the condensation of α,β -unsaturated ketones with malononitrile and
cyanoacetamide255.
(6)      By the condensation of o-nitrobenzaldehyde,  β -amino butaricacid
and methylpripiolate in gl. acetic acid256.
(7) By the knoevenagel condensation of benzaldehyde with acetoacetice
ster in presence of β-alanine as catalyst and subsequent
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cyclocondensation of the resulting benzylidene with 3-amino crotonate
257.
(8)      By the regio and chemoselective addition of  Ph2Cu(CN)Li2 to substi-
tuted N-alkylpyridium salts followed by acylation of the intermediate258
(9)      By the condensation of 1,3-diketones ,alkyl or aryl aldehydes with aq.
ammonium hydroxide in the presence of piperidine or piperidyl acetate
or potassium acetate or potassium carbonate or gl.acetic acid259-261 .
(10)    By the condensation of two moles of thiobarbituric acid, aromatic-
amines and aromatic aldehydes262-263.
MEDICINAL INTEREST 0F 1,4-DIHYDROPYRIDINE
The research on 1,4-dihydropyridine system is of current interest due to
their valuable activities as calcium channel antagonist, vasodilator, cardio-
vascular etc. beside the currently established drugs Nifedipine264-265,
Nicardipine266-267 Many dihydropyridine derivatives have been synthesized
world wide268-271. and have led to numerous second generation commer-
c ia l  product272-279 .such as Nimodip ine280-281 ,  N isod ip ine282 ,
Nitrendipine283,Amlodopine284,Felodipine285,Isradipine286, Manidipine287
and Nelva- dipine288. Some of their compounds are characterized by longer
bioactivity of greater tissue selectivity. 1,4-dihydropyridine derivatives are as-
sociated with diverse biological activities viz.
[A]  Antiarrythemic289 [B]   Antiinflammatory290
[C]  Antiallergic291 [D] Antiulcer292
[E]  Antitumor243 [F] Vasodilator293
[G]  Enzymetic294-295                              [H]Calcium channel antagonist 296-298
[I]    Antihypertensive299-300 [J] Antihypolipemic301
[K]  Antimayocardic ischemic302 [L] Cardiovascular303
[M] Photo induced relaxation246,256 [N] Antitubercular agents304
I. Nadeem et.al.,247 (38) have demonstrated the structure activity rela-
tionship of calcium channel and photo induced relaxation of novel 1,4-
dihydropyridines.  Activities of calcium channel antagonists in vitro were
detected and conclusion about structure-activity relationship (SARs), was
drawn as under:





(1) Relative potency order for C-4 phenyl substituents in ortho and meta-
position is greater then para position.
(2) C-3 nitro substitutents decrease calcium channel antagonist activity.
G. Charles et.al.,305 (39) have synthesized 1,4-dihydropyridines for
treatment of prostatic hyperplasia.
















Dihydropyridine derivatives (39) have been found to be useful in treai-
ng benign prostate hyperplasia inhibition of cholesterol synthesis (40) show-
ed ‘ki’ of 1.9 m.mol/kg in reducing urethral pressure in vivo in dog.
More recently B. M. Khadikar et.al.,306 have synthesized 1,4-
dihydropyridine derivatives (41) and tested its biological activity.
Out of many 1,4-dihydropyridine drugs only Flordipine (42) is N-substi-
tuted derivative that has proved to be very good calcium channel antagonist,
contrary to the belief proposed by D.J.Triggle307 that N-substituted 1,4-
(38)
  R1=COOCH3 / COOC2H5
  R2=COOCH3 / COOC2H5
R3 =Substituted phenyl
(39) (40)
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dihydropyridine do not show good antihypertensive activity, probably the con-




















          R=Alkyl / Aryl
N-methylnimodipine (43) was found to possess antidepressive308 char-
acteristics (20 mg.P.O reduce the immobile phase by approximately 22% com-
parison to control values), which provides excellent example of mechanism of
















                                     (43)
V. Michael et.al.,309 prepared antihypertensive and coronary vasodi-
lator N-substituted 1,4-dihydropyridine (44).
A. Daich et.al.,310 have reported calcium antagonist effect of 1,4-
dihydro-pyridines (45) and M. Suarez et.al.,311 have synthesized calcium
antagonist  modulators 1,4-dihydropyridines (46).
(41) (42)
(44)
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      R1,R2,R3= methyl / ethyl
      X=O, S, N
M. Shari fzadeh et.al . ,312  have prepared ant iconvulsant 1,4-
dihydropyridine(47) and K. Shigenobu et.al.,313 prepared cardioprotective 1,4-
dihydropyridine(48).
M. C. R. Franseen et.al.,314 have synthesized 4-substituted-1,4-dihydro-










R = CH3, CH(CH3)2,C6H5,C(CH3)3,

























R = (CH2)2O(CH2)2CH3; R1=Et / Pr / iPr
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A.Takahara et.al.,315 have designed the synthesis of N-type 1,4-dihy-
dropyridines(50)  and reported them as calcium channel blockers.
A. Motohashi et al.,316 Dihydropyridines with N-phenyl substitution and
tested for tumor specific cytotoxicity and mdr reversal activity to find out the
effects of N-phenyl substitution on activity. Asymmetric BzDHPs with different
substitution on benzoyl aromatic ring were synthesized and evaluated for tumor
specific cytotoxicity. In continuation, dihydropyridines with phenyl carbamoyl
side chain on one arm and –CN, -COOEt, -COOMe side chain on other arm
were also synthesized and evaluated as mdr reversal dihydropyridines.
R. pattan et.al.,317 have reported antihypertensive agents effect of 6-
amino-1,4-dihydropyridines(53) &(54).
In view of procuring highly potent biodynamic agents and after review-
ing literature survey on 1,4-dihydropyridines for their various methods of syn-
thesis and different biological activities, synthesis of 1,4-dihydropyridines have
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SECTION - I : Preparation and  biological  evaluation  of 2,6-Dimethyl-
3,5-N,N’-substituted-diphenyl carboxamido-4-(m-phenoxy- phenyl)-
1,4-dihydropyridines.
SECTION - II:      Preparation and biological evaluation of  6-Methyl-2-
isopropyl-4-(substituted phenyl) 3-ethyl-5-methyl-1,4-di hydropyridine-
dicarboxylates.
SECTION - III : Preparation and biological evaluation of  Methyl-
2 - i s o p r o p y l -6-methyl -3- (subst i tuted-phenyl  carboxamido)-  4-
substituted-phenyl-1,4-dihydropyridine-5-carboxylates.
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SECTION-I
PREPARATION AND BIOLOGICAL EVALUATION OF 2,6-DIMETHYL-3,5-
N,N’-SUBSTITUTED-DIPHENYLCARBOXAMIDO-4-(m-PHENOXY-PHE-
NYL)-1,4-DIHYDROPYRIDINES.
1,4-Dihydro-pyridine derivatives represents one of the most active
classes of compounds possessing wide spectrum of biodynamic activities.289-
304 In order to have potent therapeutic agents, the synthesis of  2,6-Dimethyl-
3,5-N,N’-substituted-diphenyl carboxamido-4-(m-phenoxy-phenyl)-
1,4-dihydropyridines (Xa-j). have been undertaken by the condensation of
m-phenoxy benzaldehyde and substituted- N-phenylbutanamide-3-ones
in the basic condition.
The constitution of the products (Xa-j) have been delineated by elemen-
tal analyses, IR, PMR and Mass spectral data.
The products (Xa-j)  were assayed for their in vitro biological assay
like  antibacterial activity towards S.pyogens MTCC-442, S.aureus MTCC-
96 and B.subtillis MTCC-441 (Gram positive) and E.coli MTCC-443 (Gram
negative) bacterial strains and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations i.e.
: 0 (control), 5, 25, 50, 100, 250 (μg/ml) for their MIC (Minimum Inhibitory
Concentration) values. The biological activities of the synthesized compounds
(Xa-j) were compared with standard drugs,viz., Amoxicillin, Chlorampheni-











      R=Substituted  phenyl
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 2,6-DIMETHYL-3,5-
N,N’-SUBSTITUTED-DIPHENYLCARBOXAMIDO-4-(m-PHENOXY-PHE-
NYL)-1,4-DIHYDROPYRIDINES.
(A) Preparation of N-substituted-phenyl butanamide-3-ones.
For preparation, of N-substituted-phenyl butanamide-3-ones has been
under taken according to literature318-319.
Similarly, other compounds (10a-j) were synthesized. The physical data
are recorded in Table No.10.
(B) Preparat ion of  2,6-Dimethyl-3,5-N,N’-p-p’-dichloro-diphenyl
carboxamido-4-(m-phenoxy- phenyl)-1,4-dihydropyridine (Xc).
A mixture of  m-phenoxy benzaldehyde (1.98gm, 0.01 M), N-p-chloro-
phenyl butanamide-3-one (2.11 gm, 0.02 M) in methanol (15ml) and liquor am-
monia solution (1 ml) was heated under reflux for 8 hrs. The reaction was moni-
tored by TLC.  After the completion of reaction, the reaction mixture was poured
in to crushed ice-water. The solid product so obtained was filtered, washed
with water and crystallized from Methanol. Yield : 51 %, M.P. :132 °C, (Re-
quired : C, 67.81%; H, 4.66%; N, 7.19 % for C33H27N3O3Cl2, Found :C,
67.78%; H, 4.61%; N, 7.15 %).
TLC  solvent system  Rf1: Ethyl acetate : Hexane (4.0 : 6.0)  = 0.59.
TLC  solvent system  Rf2 : Methanol       : Toluene (1.0 : 9.0)  = 0.43.
Similarly, other compounds (Xa-j) were synthesized. The physical data
are recorded in Table No.10A.
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(C) Antimicrobial activity of 2,6-Dimethyl-3,5-N,N’-substituted-diphe-
nyl carboxamido-4-(m-phenoxy- phenyl)-1,4-dihydropyridine (Xa-j).
Antimicrobial activity testing was carried out as described in Part-1(A),
Section-I, page No. 30-31. The MIC values of test solution are recorded in
Table No. 10B, 10C and 10D.
.
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)






Ph-O-Ph (sym. str., s)
C-F (str., b)
C-H (def., v,s)
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)











































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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(Xc)











































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)











































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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(Xg)














































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)






Ph-O-Ph (sym. str., s)
C-NO2 (asym str., s)

































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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(Xi)








































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)







































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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(Xc)
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(Xg)
























































































Part-1I,  Section-I...,  “Studies on dihydropyridine”. 312
(Xi)
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SECTION-II
PREPARATION AND BIOLOGICAL EVALUATION OF  6-METHYL-2-
ISOPROPYL-4-SUBSTITUTED PHENYL 3-ETHYL-5-METHYL-1,4-
DIHYDROPYRIDINE-DICARBOXYLATES.
1,4-Dihydro-pyridine derivatives represents one of the most active
classes of compounds possessing wide spectrum of biodynamic activities289-
304. In order to have potent therapeutic agents, the synthesis of 6-Methyl-2-
isopropyl-4-substituted phenyl 3-ethyl-5-methyl-1,4-di hydropyridine-
dicarboxylates (XIa-j) have been undertaken by the condensation of  ethyl-3-
amino but-2-enoate and  methyl-2-substituted- benzylidene-4-methyl-3-
oxo-pentanoates.
The constitution of the products (XIa-j) have been delineated by elemen-
tal analyses, IR, PMR and Mass spectral data.
The products (XIa-j)  were assayed for their in vitro biological assay
like  antibacterial activity towards S. pyogens MTCC-442 , S. aureus MTCC-
96 and B. subtillis MTCC-441  (Gram positive) and E. coli MTCC-443
(Gram negative) bacterial strains and antifungal activity towards Aspergil-
lus niger  MTCC-282 and Candida albicans MTCC-227 at different con-
centrations i.e.: 0(control) , 5,  25, 50, 100, 250 (μg/ml) for their MIC (Minimum
Inhibitory Concentration) values. The biological activities of the synthesized
compounds(XIa-j)  were compared with standard drugs,viz., Amoxicillin,














      R=Substituted  phenyl











































326Part-1I,  Section-II...,  “Studies on dihydropyridine”.
EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 6-METHYL-2-ISO-
PROPYL-4-SUBSTITUTED PHENYL 3-ETHYL-5-METHYL-1,4-DI
HYDROPYRIDINE-DICARBOXYLATES.
(A) Preparation of Ethyl(2z)-2-(m-nitro benzylidene)-4-methyl-3-
oxopentanoate.
A mixture of ethyl 4-methyl-3-oxopentanoate (1.58 gm, 0.01 M), m-nitro
benzaldehyde (1.51 gm, 0.01 M)  in ethanol (20 ml) in the presence of piperi-
dine was stirred at 25-35°C for 10 to 12 hrs. The reaction was monitored by
TLC. The reaction mixture was poured in to water, filtered, washed with water,
dried and recrystallized from ethanol. Yield : 42%, M.P. : 132°C, (Required :
C, 60.64 %; H, 5.45 %; N, 5.05% for C14H15NO5, Found :C, 60.59%; H,
5.41%; N, 5.00%).
TLC solvent system   Rf1: Ethyl acetate : Hexane (9.0 :1.0)  = 0.53.
TLC  solvent system  Rf2: Methanol        : Toluene (1.5 : 8.5) = 0.56.
Similarly, other compounds (11a-j)  were synthesized. The physical data
are recorded in Table No.11.
(B) Preparation of Ethyl (2E)-3-aminobut-2-enoate.
A mixture of ethyl aceto acetate (1.30gm, 0.01 M), ammonia solution (25%)
(2.72 ml, 0.04 mol ) in methanol (10ml) in the presence of catalytic amount of
acetic acid was stirred for 2 hrs. It got separated into two layers of water and
product. The two layers were separated with the help of separatory funnel.The
separated layer was Ethyl (2E)-3-aminobut-2-enoate. Yield : 58%, M.P.:29°C,
(Required:C, 55.80%;H, 8.58%;N,10.84 for C6H11NO2, Found :C, 55.75%;
H, 8.52%; N,10.79%).
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(C) Preparation of 6-Methyl-2-isopropyl - 4(m-nitro phenyl) 3-ethyl-5-
methyl-1,4-di hydropyridine-dicarboxylate (XIa-j) .
A mixture of Ethyl(2z)-2-(m-nitrobenzylidene)-4-methyl-3-oxopentanoate.
(2.77 gm,0.01 M), Ethyl (2E)-3-aminobut-2-enoate.(1.52gm,0.012 M) and Anhy-
drous potassium carbonate (2.74 gm, 0.02 M) in dimethyl formamide (20 ml)
was heated under reflux for 8 to10 hrs.The reaction was monitored by  TLC. The
reaction mixture was allowed to cool at room tempreture. The solid product so
obtained was filtered, washed with water, dried and cystallized from dimethyl
formamide. Yield : 38%, M.P. :128°C, (Required : C, 61.84 %; H, 6.23 %; N,
7.21 % for C20H24N2O4, Found : C, 61.78%; H, 6.16%; N, 7.17%).
TLC solvent system    Rf1: Ethyl acetate :Hexane        (2.5 : 7.5)  = 0.48.
TLC solvent system    Rf2 : Methanol       :Chloroform (0.5 : 9.5)  = 0.44 .
.
Similarly, other compounds (XIa-j)  were synthesized. The physical data
are recorded in Table No.11A.
(B) Antimicrobial activity of 6-Methyl-2-isopropyl -4-substituted phe-
nyl 3-ethyl-5-methyl-1,4-di hydropyridine-dicarboxylate (XIa-j).
Antimicrobial activity testing was carried out as described in Part-1(A),
Section-I, page No. 30-31. The MIC values of test solution are recorded in
Table No. 11B, 11C and 11D.
































































































































   




   




























   




   




























   




   




























   




   





























   




   





























   




   





























   




   

























   





   




   






























   




   





























   




   




















































































































































































   




   






























   




   






























   




   






























   




   





























   




   





























   




   






























   































   





   




































   



































   


























































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)







IR SPECTRAL STUDY OF 6-METHYL-2-ISOPROPYL-4-(p-FLUORO PHEN-
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)





































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)










































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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(XIf)















































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)







































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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(XIh)














































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)








































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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(XIf)
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   (XIh)
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SECTION-III
PREPARATION AND BIOLOGICAL SCREENING OF METHYL-2-ISO-
PROPYL-6-METHYL-3-(SUBSTITUTED-PHENYLCARBOXAMIDO-4-SUB-
STITUTED-PHENYL-1,4-DIHYDROPYRIDINE-5-CARBOXYLATES.
1,4-Dihydro-pyridine derivatives represents one of the most active
classes of compounds possessing wide spectrum of biodynamic activities289-
304. In order to have potent therapeutic agents, the synthesis of Methyl-2-
isopropyl-6-methyl-3-(substituted phenyl carboxamido)-4-substituted
phenyl-1,4-dihydropyridine-5-carboxylates (XIIa-j) have been undertaken
by the cyclocondensation of  one  mole of methyl-3-amino but-2-enoate with
different one mole of 2-substituted-benzylidene-4-methyl-3-oxo-N-phenyl
pentanamides.
                                                                      (XIIa-j)
    R & R1= Substituted phenyl
The constitution of the products (XIIa-j)  have been delineated by elemental
analyses, IR, PMR and Mass spectral data.
         The products (XIIa-j)  were assayed for their in vitro biological assay
like  antibacterial activity towards S. pyogens MTCC-442 , S. aureus MTCC-
96 and B. subtillis MTCC-441  (Gram positive) and E. coli MTCC-443
(Gram negative) bacterial strains and antifungal activity towards Aspergil-
lus niger  MTCC-282 and Candida albicans MTCC-227 at different con-
centrations i.e.: 0(control), 5,  25, 50, 100, 250 (μg/ml) for their MIC (Minimum
Inhibitory Concentration) values. The biological activities of the synthesized












































R , R1= substituted phenyl
 Dimethyl-
 formamide 
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL SCREENING OF METHYL-2-ISO-
PROPYL-6-METHYL-3- (SUBSTITUTED-PHENYLCARBOXAMIDO-
4-SUBSTITUTED-PHENYL-1,4-DIHYDROPYRIDINE-5-CARBOXYLATES.
(A) Preparationof  3-4-dichloro-phenyl-4-methyl-3-oxopentanamide.
The synthesis of  3-4-dichloro-phenyl-4-methyl-3-oxopentanamide was
undertaken according to the literature procedure.318-319. Yield :54 %, M.P.
:153°C, (Required:C, 52.57%;  H, 4.78%;  N, 5.11% for C12H13NO2Cl2, Found
: C, 52.52 %; H, 4.68 %; N, 6.52 %).
TLC solvent system    Rf1: Ethyl acetate : Hexane       (1.0 : 9.0)  = 0.48.
TLC  solvent system   Rf2: Methanol        : Chloroform(0.5 : 9.5)  = 0.51.
Similarly, other compounds  were synthesized.
(B) Preparation of N-(3,4-dichlorophenyl)-4-methyl-2-(m-nitrobenzylidene)-
3-oxopentanamide (12f).
For preparation, refer  Part-II, Section-II, page No. 326-327.
Yield: 47%, M.P.:183°C, (Require:C, 56.04%; H, 3.96%; N, 6.88 % for
C19H16N2O4Cl2, Found : C, 56.00 %; H,  3.91 %; N, 6.81%).
TLC solvent system    Rf1:  Ethyl acetate :  Hexane      (2.5 : 7.5) = 0.48.
TLC  solvent system  Rf2: Methanol        :Chloroform(1.0 : 9.0) =  0.41.
Similarly, other compounds (121-10)  were synthesized. The physical data
are recorded in Table No.12.
(C) Preparation of Methyl (2E)-3-aminobut-2-enoate.
For preparation, refer  Part-II, Section-II, page No.326-327.
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Yield : 72%, M.P.: 81°C, (Required : C,52.16%; H, 7.88%; N,12.17% for
C5H9NO2, Found : C,52.09 %; H, 7.82%; N,12.11%).
(D) Preparation of Methyl-2-isopropyl-6-methyl-3-(3,4-dichloro phe-
nyl carboxamido)-4-substituted phenyl-1,4-dihydropyridine-5-carboxy-
late (XIIa-j).
A mixture of N-(3,4-dichlorophenyl)-4-methyl-2-(m-nitrobenzylidene)-3-
oxopentanamide (12f) (4.07 gm, 0.01 M), methyl (2E)-3-aminobut-2-enoate (1.38
gm, 0.012 M) and potassium carbonate (2.74 gm, 0.02 M) in dimethyl
formamide (20 ml) was heated under reflux condition for 8 to 10 hrs. The reac-
tion was monitored by TLC. The reaction mixture was allowed to cool at  room
temperature. The reaction mixture was then poured in to cold water. The solid
product  so obtained was filtered, washed with water, dried and crystallized
from dimethyl formamide. Yield : 49%, M.P. :198°C, (Required : C, 57.15 %;
H, 4.60 %; N, 8.83 % for C20H24N2O4, Found : C, 57.08 %; H, 4.53 %; N,
8.78 %).
TLC  solvent system  Rf1 : Ethyl acetate : Hexane       (3.0 : 7.0) = 0.62.
TLC  solvent system  Rf2 : Methanol        : Chloroform(0.5 : 9.5) = 0.59.
Similarly, other compounds (XIa-j)  were synthesized. The physical data
are recorded in Table No.12A.
(E) Antimicrobial activity of Methyl-2-isopropyl-6-methyl-3-(substi-
tuted phenyl carboxamido)-4-substituted phenyl-1,4-dihydropyridine-5-
carboxylates (XIIa-j).
Antimicrobial activity testing was carried out as described in Part-I(A),
Section-I, page No. 30-31. The MIC values of test solution are recorded in
Table No. 12B, 12C and 12D.
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IR SPECTRAL STUDY OF METHYL-2-ISOPROPYL-6-METHYL-3-(m-
TRIFLUOROMETHYL-PHENYL CARBOXAMIDO)-p-CHLOROPHENYL-













































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C=C & C-C (str., v)
C-H (i.p. def., m)
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(XIId)














































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (sym. def., m)
C=C & C-C (str., v)
C-H (i.p. def., m)



































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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(XIIf)



















































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H(str., s)
C=C & C-C (str., v)
C-H (i.p. def., m)











































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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(XIIg)

















































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C=C & C-C (str., v)
C-H (i.p. def., m)







































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
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(XIIj)
IR SPECTRAL STUDY OF METHYL-2-ISOPROPYL-6-METHYL-3-(p-




















































Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C=C & C-C (str., v)
C-H (i.p. def., m)










































* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
365Part-1I, Section-III...,  “Studies on dihydropyridine”.



















































































366Part-1I, Section-III...,  “Studies on dihydropyridine”.
(XIId)
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(XIIf)
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(XIIg)




























































































369Part-1I, Section-III...,  “Studies on dihydropyridine”.









































































































































- Ar-C (i to v)



























































































































































































































































































































































































































































































m/z = 110 (M+2),
(B.P.),
(XIId),



















































































































































































































































































































































































































































































































































































































































































































































































381Part-1I, Section-III...,  “Studies on dihydropyridine”.
   
   
   











   
   
   
   
   
   
   
   
   





























































































































































































































   
   
   
   




















































   
   
   
   

























































































































































































































































































































































































































































































































































.   
   
   
   


































































   
   
   
   
   
   
   
   
   
   
   


























































































































































































   
   
   
   















































































































































































































































































































































































































































































































   
   
   
   
   
   












   
   
   
   
   
   
   
   
   





























































   
   
   
   























































































































































































































   
   
   
   








































































Part-II,  References...,  “Studies on dihydropyridine”. 384
REFERENCES
238. Huang, Fu Chin, Clara J., Jones Howart; Chem. Abstr., 101, 110747(1984).
239. B.Chekavichus et.al.; (Latvin institue of organic synthesis, Riga. Latvia, LV-1006);
Chem. Heterocycl. Compd. (N.V.) (Pud. 1998), 33 (7), (1997) 799-Sou(Eng.); Chem, Abstr.,
128, No.11, 127907t-562 (1996).
240. Hermandez- Gallegoes, F. PA  Lehmann, E. Hung, F. Posadas, E. Herman dez Galle-
gos; Eur. J. Med. Chem., 355-364 (1995).
241. K.Ohsumi, K. Ohishi, Y. Morinaga, R. Nakagava, Y. Suga, T. Sekiyama, T. Tsuji, T. Tsurui;
Chem. Pharm. Bull., 13 (5), 818-828 (1995).
242. F.Bossert et.al; Ger. Offen., 1,923,990; Chem. Abstr., 74,53543p (1971).
243. A. Zidermane, G. Duburs. A. Zibere, Lat. V PSR; Zinat. Akad. Vestes, 4, 77 (1970),
Chem. Abstr., 75, 47266 (1971).
244. S. M. Jain, R. Kant, S. Devi, K. L. Dhar, S. Singh, S. Bani, G. B. Singh; Ind. J.Chem.
29B, 95-97 (1990).
245. Harada K, Kawahara J, Okada Y, Uzamaki H, Kusaka M, Tokiwa T; Jpn. J. Pharmacol.,
Nov; 78 (3), 261-8 (1990).
246. Miri Ramin, Howlett Susan E., Knaus Edward E. (Faculty of Pharmacy,Pharmaceut ical
Sciences, University Alberta, Edmonton, AB Can. T6G2N8); Arch. Pharm., (Weinhein,
Ger.) 1997, 330 (9-10), 290-294 (Eng.); Chem. Abstr., 128, No. 6, 61409-530 (1998).
247. I. Nadeem et.al.; (Faculty of Pharmacy, Pharmaceutical Sciences U n i v e r s i t y  o f
Albe-rta, Edmonton, AB Can. T6G2N8), Drug Dev. Res. 1997, 42 (3/4),  120-130
(Eng);Chem. Abstr., 128, No. 26, 321541j-570 (1998).
248. K. Isamu et.al; (department of Chemistry, Faculty Engineering, Gifu University, Ja
pan, (501) 1997, (11), 1321-1324 (Eng.); Chem. Abstr.,128, No. 8,88763w-561(1998).
249. Niwa Seili et.al. (Ajinomoto Co., Inc, Japan); PCT Int. Appl., WO 19 32,446 (CI.C0
 7d211/30), 1 July 1999, Jp Appl. 1998/303, 067, 23 Oct.1998; 101, pp (Japan);
Chem.Abstr., 131, No. 6, 73562t-738(1999).
250. S. G. Jagadeesh, G. L. David Krupadanam and G. Srimannarayana; Ind. J. Chem.,
36(2), 965 (1997).
251. C. Safak, I. Sahin, R. Sunal; Arzneim-forsch/ Drug Res., 40(1), 119-122 (1940).
252. Hernandez-Gallegos, F.PA Lehmann, E. Hung, F. Posadas, E. Hernandez-
Gallegos; Eur.J. Med. Chem., 30, 355-364 (1995).
253. P. Murugan and V. T. Ramakrishnan; Indian J. Chem., 40B, pp.78 -781 (2001).
254. A. Shah, H. Geraiya, Y. Motohshi, M. Kawase, S. Saito, H. Sakagami, K. Saton, Y.
Tada; J. Anticancer, 203, 323-78 (2000).
255. A. V. Sauin et.al., (Department of Chemistry, Moscow state Univ.,Moscow , Rusia
(119894); Rus. J. Org. Chem., 1997, 33 (2),  205-212 (Eng.); Chem. Abstr., 128, No.13,
153990j-587 (1998).
Part-II,  References...,  “Studies on dihydropyridine”. 385
256. Fujii Hirofumi, Hayashi Shunichi (Nitto Denko Corp., Japan); Jpn. Kokai,Tokkyo Koho
JPW 175,953 (98 175,953) (Cl.C07D 211/90,30 June 998, Appl. 96/340,123, 19 Dec.
1996; 13 pp. Japan; Chem. Abstr., 129, No.8, 95407a-690 (1998).
257. Castelli, Eugenio et.al.; PCT.Int. Appl. Wo 95 07,698(Cl. C07D 211/90), 26 Feb.
1998, IT Appl. 96/1, 708, 23- Aug.1996, 20 pp.(Eng.); Chem. Abstr., 123, No.16, 192556s-
517 (1998).
258. Bennasar, M-Liuisa et.al.(Laboratory of Organic Chemistry, Faculty of Pharmacy, Univ.
of Barcelona, Barcelona Spain 08028); Tetradedron Lett., 1998, 39(50), 9275-9278
(Eng.);  Chem. Abstr . ,  130 ,  No.10, 124977w-709 (1999).
259. G. Inoue; Nippon Kagaku Zasshi, 79, 1243-6 (1958); Chem. Abstr., 54,  24716 (1960).
260. G. Inoue; Nippon Kagaku Zasshi, 80, 1061-3 (1959); Chem. Abstr., 55, 3586 (1961).
261. G. Inoue, N. Sugiyama, T. Ozawa; Nippon Kagaku Zasshi, 82, 1272-4(1961); Chem.
Abstr., 57, 15067 (1960).
262. V. K. Ahluwalia and Umashankar Dasl, Ind. J. Chem., Sect-B, 35B, 852 (1996).
263. V. K. Ahluwalia and Pooja Sharma and Bindu Goyal; Ind. J. Chem., 36B,1059 (1997).
264. R. Nanda Kumar, T. Suresh and P. S. Mohan; Oriented J. Chem., Vol.18(1), 93-96 (2002).
265. Vater W., Kroneberg G., Hoffmeifer F., Kal ler H., Meng K., Oberdorf A., Plus
W,Schlossmann K. and Stoepelk K.; Arzneim-forsch, 22, (1972).
266. Iwanami M. et.at.; Chem. Pharm. Bull, 27, 1426 (1979).
267. Takenaka T., Usnda S. Nomara T., Maeno H. and Sado T.; Arzneim-forsch, 26, 2172 (1976).
268. Bossert F. and Vater W.; Med. Res. Rev. 9, 291 (1989).
269. Kastrons V., Vitolins R. and Duburs G.; Khim Farm Zh, 24, 14 (1990).
270. Triggle D. J. et. al.; Med. Res. Rev. 9, 123 (1989).
271. Janis R. A, Silver P. and Triggle D. J.; Adv. Drug Res., 16, 307 (1987).
272. Oht Suka M., Yokota M., Kodama I., Yamada K. and Shibata S.; Gen. Pharmacol. 20, 539
(1989).
273. Sausing A. and Duburs G.; Heterocycles, 27, 269 (1988).
274. Bossert F. Meyer H. and Wehinger E.; Angew. chem., 93, 755 (1981).
275. Bossert F. Meyer H. and wehinger E.;  Angew.  Chem., Int. Ed. Engl., 93, 762 (1987).
276. Stout D. M. and Meners; A I, Chem. Rev., 82, 223 (1982).
277. Kuthan J. and Kurfurst A.; Ind. Eng. Chem. Prod Res. Dev.,  21,191 (1982).
278. Eisner U. and Kuthan J. ; Chem. Rev., 72, 1 (1972).
279. Freedman D. D. and Waters D. D.; Drugs, 34,  578 (1987).
280. Kazda S. and Towart R. ; Br. J. pharmacol., 72,  pp. 582-83 (1981).
281. Tanaka K. et. al.; Arzneim-forsch, 32, 1529 (1982).
282. Kazda s. et. al.; Arzneim-forsch, 30, 2144 (1980).
283. Stoepel K., Heise A. and Kazda S.; Arzneim-forsch, 31, 2056 (1981).
284. Arrowsmith J. E. et.al; Pharmacologist, 27, 290 (1985).
285. Nyborg N. C. B. and Mulvany M. J.; J. Cardiovase. Pharmacol., 6, 499 (1984).
Part-II,  References...,  “Studies on dihydropyridine”. 386
286. Hof  R. P., Scholtusik G., loutzenhiser R., Vuorela H. J. and  Neumann P.; J.cardiovase. Pharmacol.,
6, 394,(1984).
287. Meguro K.,  Aizawa M.,Sohda T., kawamatsu Y., and  Nagaoka A.; Chem. Pharm. Bull., 33, 3787(1985).
288. Furuta T., Shibata S., kodama I. And Yamada K.; J. Cardiovase. Pharmacol., 5, 836 (1983).
289. H. Masakatu, K. Kenichi, S. Yasuchiko, H. Masakazu, K. Osumu, H. Hiroyoshi; Chem. Abstr.,
130, No. 3, 24915f-579 (1999).
290. R. C. Johnson, D. J. Taylor, V. A. Kenneth, C. soan; US Pat. 4, 758, 669, Chem. Abstr., 109,
149336 (1988).
291. K. Cooper, F.M. Jonatham;Eur. Pat. Appl. EP 294, 274, U S Pat. 4, 758, 669,Chem Abstr.,
110, 231441 (1989).
292. F. Marco, Z. Andrea, G. Carmelo, M. Germini; Eur. Pat. 272, 693; Chem. Abstr.,109, 190259
(1988).
293. E. Wehinger, H. Meyer,  A. Knorr, K. Stanislaw; Chem. Abstr., 107,  217482 (1987).
294. Marchalin Stefan, et.al. (department of chemistry, Solvak Tech. Univ., Bartialava, Solvakia SK.
(81237); Heterocycles 1998, 1943-1958 (Eng.), Japan ; Chem. Abstr., 131, No.3, 24915f-569
(1999).
295. Fujii Masayuki et.al. (Department of chemistry, Kinki univ., Fukuoka,(Japan 820);
Trends Heterocycl. Chem., 1997, 5, 17- 36(Eng.), Research Trands; Chem. Abstr.,
130, No.6. 66006-669 (1999).
296. Miwa Seiji et.al., (Ajinomato co. inc. Japan); PCT Int. Appl. Wo 99 32,446 (Cl.C07d
211/90), 1, July 1999, Jp Appl. 1998/303, 067, 23 Oct.1998 101 pp. (Japan); Chem.
Abstr., 130, No.6, 73562-738 (1999).
297. V. K. Ahluwalia and Bindu Goyal; Ind. J. Chem., Vol. 35B, Oct (1996), pp.1021-1025.
298. R. K. Khajuria et.al.; Ind. J. Chem. Vol. 32B, Sept. 1993, pp. 981-983.
299. Nagarathnam, Dhanapalau et.al. (Department of Chemistry, pharmaceuticology and
Pharmaceutical, Operations, Sunaptic Pharmaceutical corpration, Paramus, NT 07652
USA);J.Med.Chem.,1998,42(26), 5320-333(Eng), American Chemical Society’
,Chem. Abstr.,130(9), 110137-87 (1999).
300. Zhang Sauqi et. al. (Department of Pharmacy, Xijing Hospital, fourthmiitary medical
Univ. ( CITY 186, Peop. Rep. China) Yaexue Vuebao1998, 33(10) 789-792(ch); Chem.
Abstr., 130, No.12 ,15 3554m -648 (1999).
301. Kulbhushan Rana, Balbir kaur and Baldev Kumar; Ind. J. Chem., 43B, 1553 (2004).
302. Z. M. Yan, Y. M. Ding, Y. Xuebao; Chem. Abstr., 106, 32859 (1987).
303. Karup, Gunnal et.al. (A/S Gea Pharmaceutic Fabrik, Den.); PCT Int;Appl. Wo 99 25,
688 (CI. C07D 211/90),27 May 1999, DK Appl. 1997/1,299, 14 Nov . 1997; 37 pp.(Eng);
Chem. Abstr., 131, No. 1, 5189b-627(1999).
304. H. Gevariya , B. Desai , V. Vora,  A. K. Shah; Hetero cycliccommunication , 7(5), 481
(2002).
Part-II,  References...,  “Studies on dihydropyridine”. 387
305. Gluchowski Charles et.al. (Synaptic Pharma. Co. USA); U. S. US 5,767,131 (CI.
514-318; A01N 43/46) 16 Jan. 1998, WO Appl. 94 / US, 3, 852, 5 Apr. 1994; 160 pp.;
Chem. Abstr., 129(6), 67709p-661(1998).
306. B. M. Khadilkar et.al. ; Ind. J. Chem. , Vol. 40B,  pp. 82-86, Jan. 2001.
307. D.G.Triggle ; Drugs acting on icon channels and membranes, Comprehensivemedicinal
chemistry, 3,1047 (1990).
308. H. Meyer  et.al; DE 4133257 and EP 5336603 (Bayer A. G.).
309. V. Michael  et.al; Ger. Offen., 2, 405,658; Chem. Abstr., 81, 169440b (1974).
310. A. Daich, Milostav Chudik, Stefan Marchlin, Peter Knesl  and Bernard Decroix, J.
Het.Chem.,37, 1549 (2000).
311. M. Suarez, Yamila Verdecia, Estael Ochoa, Nazario Martin, RobertoMartinez ; J.
Het.Chem., 37, 735 (2000).
312. M. Sharifzadeh, A. Shafiee, N. Rastkari;Daru, 12 (2), (2004).
313. K. Shiganobu, H. Tanaka;Cardiovascular Drug Reviews, 18(2), 93-102 (2000).
314. M. C. R. Franseen, A. Sobolev, A. de Groot; J. Org. Chem., 67, 401-10 (2002).
315. A. Takahara, T. Yamamoto, S. Niwa;Bioorganic & Med. Chem. Lett., 16 (4), 798-802
(2006).
316. Engi, H.; Sakagami, H.; Kawase, M.; Parecha, A.; Manvar, D.; Kothari, H.; Adlakha, P.;
Shah, A.;Motohashi, N.; Ocsovszki, I.; Molnar, J.; In Vivo 20, 637-44, 2006.
317. Rafael Leon,Manuela G.Lopez, Mercedes Villarroya, Euro. J. of Med. Chem.43,668-674,(2008)
318. G.V. Jadhav, J. Indian Chem. Soc.; 7, 669-671 (1930).
319. B. Desai, D. Sureja, Y. Naliapara, A. Shah,  A. K. Saxenab, Bioorganic & Med. Chem.; 9,
1993–1998 (2001).
